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ABSTRACT: A novel series of fully synthetic 8-azatetracyclines
waspreparedandevaluatedforantibacterialactivity.Compounds
were identiﬁedthat overcome both eﬄux (tet(K)) andribosomal
protection (tet(M)) tetracycline resistance mechanisms and are
active against Gram-positive and Gram-negative organisms. Two
compounds were identiﬁed that exhibit comparable eﬃcacy to marketed tetracyclines in in vivo models of bacterial infection.
’INTRODUCTION
The tetracycline class of antibacterial agents has seen wide-
spread clinical use for over 50 years due to its broad spectrum anti-
bacterial activity.
1 Tetracyclines inhibit bacterial growth by prevent-
ing protein biosynthesis through binding to the 30S ribosome,
thereby blocking the binding of aminoacyl-tRNA to the acceptor
site.
2 This class includes a number of naturally occurring com-
pounds, such as chlorotetracycline (1)
3 and tetracycline (2),
4 as
well as several semisynthetic analogues, such as doxycycline (3)
5
and minocycline (4) (Figure 1).
6 In addition to their use as anti-
biotics for serious infections, tetracyclines have also been pre-
scribedforuseinacneandrosacea.
7Aswithmanyclassesofanti-
biotics, widespread use of tetracyclines has led to resistance and
has limited their use in more complicated bacterial infections.
8,9
Two major bacterial resistance mechanisms have been identi-
ﬁed for tetracyclines: (1) active transport from bacterial cells via
eﬄuxpumps
10and(2)ribosomalprotection.
11Theeﬄuxpumps
are comprised of inner membrane tetracycline eﬄux proteins that
were ﬁrst identiﬁed in Gram-negative organisms (tet(A-E))
10a,10b
and were later found in Gram-positive bacteria (tet(K-L)).
10c The
ribosomal protection mechanism (tet(M-O)) involves the expres-
sion of proteins that bind to the ribosome and allow protein
synthesis to proceed even in the presence of tetracyclines. The
exact mechanism by which this occurs remains unclear. Since
these early discoveries, the number of eﬄux and ribosomal protec-
tion mechanisms identiﬁed has increased.
12
The presence of the strongly activating 10-hydroxy group
readily enables chemical modiﬁcation of the tetracycline D-ring
atthe7-and9-positions.Thisstrategyledtotheintroductionof
the 7-dimethylamino group in compounds 4-6, all of which
have demonstrated improved activity in bacterial strains bear-
ing eﬄux pump resistance mechanisms. More recently, the
9-substituted glycylcyclines, such as tigecycline (5),
13 and the
aminomethylcyclines, such as amadacycline (6),
14 have shown
improvedactivityfor resistant organisms bearing theribosomal
protection mechanism.
In 2005, Myers and co-workers published a fully synthetic
route to the tetracyclines, the key step of which involves the
Michael-Dieckmann condensation of the AB precursor 8 with
structurally diverse D-ring precursors.
15,16 This route provides
potential access to a broad range of tetracyclines that are inacces-
sible via traditional semisynthesis.
17 One example of this is the
introduction of a nitrogen atom into the D-ring, resulting in
“azatetracyclines.”One7-azatetracyclineandone9-azatetracycline
were disclosed in Myers original work, resulting in compounds
with only modest antibacterial activity. Herein we demonstrate
this powerful approach using pyridyl D-ring precursors 7 to
generate novel 8-azatetracyclines, 10 (Scheme 1).
’RESULTS AND DISCUSSION
Chemistry. To explore 7- and 9-substituted-8-azatetracyclines,
werequiredintermediatesthatcouldbereadilymodifiedeitherprior
toorafterconstructionoftheprotectedcompound9.Thus,the
halopyridines15and16werepreparedaccordingtoSchemes2
and 3. 3,5-Dichloroisonicotinic acid was treated with sodium
b e n z y l a t et og i v ec o m p o u n d12, which was esterified to the
phenyl ester 13 by conversion to the acid chloride, followed by
treatment with phenol and 4-(dimethylamino)pyridine (DMAP).
Suzuki coupling
18 using methylboronic acid and PdCl2Cy2
catalyst
19 gave the parent D-ring precursor 14 in good yield.
N-Oxide formation with hydrogen peroxide in acetic acid
followedbytreatmentwitheitherphosphorousoxychlorideor
phosphorousoxybromide gave 15a and 15b, respectively. For
15a, the reaction gave a 4.5:1.0 ratio of the desired regioi-
somer, while a 25:1 ratio was observed for 15b.B o t hd e s i r e d
regioisomers were isolated in pure form by recrystallization.
The regiochemistry was assigned by conversion to the dimethyla-
mino compound 15c through a palladium-mediated amination.
20
1H NMR studies indicated an nOe between the methyl
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groups of the amine and the adjacent ring methyl group. The
methoxy derivative 15d was prepared from 15b by treatment
with sodium methoxide in 2-methylpyrrolidinone (NMP) at
120C. This gave the acid directly, which was re-esterified tothe
phenyl ester.
The dihalo compounds 16a and 16b were prepared by N-
oxidation of 15a and 15b followed by treatment with POBr3
(Scheme 3). Yields were typically moderate (45-50%), with
reductionoftheN-oxidetogivethestartingpyridines15observed
asmajorsidereactionsinbothcases.Palladium-mediatedcoupling
of 16b with t-butylcarbamate gave a ∼2.5:1 mixture of regioi-
somers, which were readily separated after conversion to the free
amine 16c upon treatment with HCl. Treatment of 16c with
sodium nitrite in the presence of HF-pyridine gave the ﬂuoro
derivative 16d in good yield.
21 Similarly, a 2.4:1.0 ratio of
regioisomers was observed in the palladium-mediated reaction
of 16b with dimethylamine to give 16e and 16f. Interestingly, the
regioselectivitycouldbereversedbyheating16binthepresenceof
dimethylaminewithoutcatalysttogive16fasthemajorisomerina
3:1 ratio.
The 9-amino D-ring precursors 18a and 18b were prepared
according to Scheme 4. Once again, palladium-mediated cou-
plings using t-butylcarbamate proved to be highly eﬀective for
Figure 1. Examples of naturally occurring (1 and 2) and semisynthetic (3-6) tetracyclines.
Scheme 1. Fully Synthetic Approach to the 8-Azatetracyclines
Scheme 2. Synthesis of D-Ring Precursors for 7-Substituted-
8-azatetracyclines
a
aReagents and conditions: (i) NaH (2 equiv), BnOH, NMP,
80 C; (ii) (COCl)2,c a t .D M F ,C H 2Cl2; (iii) PhOH, Et3N,
DMAP, CH2Cl2;( i v )C H 3B(OH)2,P d C l 2Cy2,K 3PO4,t o -
luene, water, 100 C; (v) H2O2,A c O H ,8 0C; (vi) POCl3,
toluene, 100 C; (vii) POBr3, toluene, 100 C; (viii)dimethy-
lamine in THF, Pd2dba3,X a n t p h o s ,K 3PO4, 1,4-dioxane,
100 C (sealed); (ix) NaOMe, NMP, 100-120 C.1513 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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introduction of the amino group. Further protection of the mono-
Boc intermediates 17with Boc2O and DMAPin DMF gavethe
di-Boc precursors 18.
Synthesis of the 8-azatetracyclines is outlined in Scheme 5.
Most of the D-ring precursors were lithiated with lithium
diisopropylamide (LDA) at -78 C, followed by treatment with
the enone 8.W a r m i n gt o-20 C yielded the fully protected
tetracycline precursors 19. For D-ring precursors 16a, 16d,
and 18b, a one-pot reaction was performed in which lithium
bis(trimethylsilyl)amide (LHMDS) was added to a -78 C
Scheme 3. Synthesis of D-Ring Precursors for 7,9-Disubstituted-8-azatetracyclines
a
aReagents andconditions:(i) for15a,mCPBA, CH2Cl2;for15b,H 2O2,AcOH, 80C;(ii) POBr3, toluene, 100C;(iii)BocNH2,Pd 2dba3,Xantphos,
Cs2CO3, 1,4-dioxane, 80 C; (iv) HCl, 1,4-dioxane; (v) HF-pyridine, NaNO2, pyridine; (vi) dimethylamine in THF, Pd2dba3, Xantphos, Cs2CO3, 1,4-
dioxane, 60 C (sealed).
Scheme 4. Synthesis of D-Ring Precursors for 9-Amino-8-azatetracyclines
a
aReagents and conditions: (i) BocNH2,P d 2dba3, Xantphos, Cs2CO3, 1,4-dioxane, 80 C; (ii) Boc2O, DMAP, DMF.
Scheme 5. Synthesis of 8-Azatetracyclines
a
aReagents and conditions: (i) for 14, 15b-d, 16e, and 18a, LDA, TMEDA, -78 C, THF then 8, -78 Ct o-20 C; (ii) for 16a, 16d, and 18b,
LHMDS,8,THF,-78Cto-20C;(iii)CH3B(OH)2orPhB(OH)2,PdCl2dppf2-CH2Cl2,K 3PO4,toluene,1,4-dioxane,water,100C;(iv)BocNH2,
Pd2dba3, Xantphos, K3PO4, 1,4-dioxane, 100 C; (v) aqueous HF, CH3CN or 1,4-dioxane; (vi) 10% Pd/C, H2, HCl, MeOH, 1,4-dioxane.1514 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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solution of the precursor and the enone 8 followed by
warming to -20 C. Yields varied from 20 to 84% depending
on substrate, with larger reaction scales generally providing
better results. The LHMDS procedure also typically gave
higher yields but was only possible on the more highly electron
deﬁcient D-ring precursors. The 7-bromo intermediate 19c was
further derivatized at this stage via Suzuki couplings with methyl-
boronic acid and phenylboronic acid to give 19d and 19e,
respectively. Similarly, palladium-mediated amination with 19h
and t-butylcarbamate provided the 7-chloro-9-amino compound
19j. Deprotection of the intermediates 19 with HF followed by
hydrogenation in the presence of palladium on carbon gave the
ﬁnal 8-azatetracyclines 20a-k.
To compare the 8-azatetracyclines directly to tigecycline, the
9-glycylamido-8-azatetracyclines21a-cwereprepared(Scheme6).
TheBocgroupsofcompounds19j-lweredeprotectedwithHClin
1,4-dioxane. Treatment with bromoacetylchloride in THF followed
by excess t-butylamine gave the acylated intermediates, which
were deprotected under standard conditions to give the ﬁnal
analogues 21a-c.
The bromopyridine intermediates proved to be useful for the
introduction of alkylamines via palladium-mediated aminations
and alkyl groups via Suzuki couplings, ultimately providing the
9-alkylamino-8-azatetracyclines24and9-alkyl-8-azatetracyclines
26 (Scheme 7). Thus, 19h was treated with various amines in
the presence of Pd2dba3 and 9,9-dimethyl-4,5-bis-(diphenyl-
phosphino)xanthenes (Xantphos) in 1,4-dioxane at 100 C.
Potassium phosphate was found to be the most eﬀective base
for this transformation, with cesium carbonate and sodium t-
butoxide leading to rapid decomposition. Low yields were
generally observed due to decomposition of both the starting
material and products upon heating. Reaction times of 2-4h
were eventually settled on as a balance between product forma-
tion and decomposition. Copper-catalyzed aminations were also
Scheme 6. Synthesis of 9-Glycylamido-8-azatetracyclines
a
aReagents and conditions: (i) HCl, 1,4-dioxane; (ii) bromoacetylchloride, THF then t-BuNH2,5 0C; (iii) aqueous HF, CH3CN or 1,4-dioxane; (iv)
10% Pd/C, H2, HCl, MeOH, 1,4-dioxane.
Scheme 7. Synthesis of 7,9-Disubstituted-8-azatetracyclines
a
aReagents and conditions: (i) R2R3NH2, Pd2dba3, Xantphos, K3PO4 or Cs2CO3, 1,4-dioxane, 100 Co rn-propylamine, CuI, 2-acetylcyclohexanone,
K3PO4,DMF,100C;(ii)LHMDS,THFthenBoc2OorCbzCl;(iii)LDA,TMEDA,-78C,THFthen8,-78Cto-20CorLHMDS,8,THF,-
78Cto-20C;(iv)aqueousHF,CH3CN,or1,4-dioxane;(v)10%Pd/C,H2,HCl,MeOH,1,4-dioxane;(vi)R2B(OH)2,(Ph3P)4Pd,K3PO4,toluene,
1,4-dioxane, H2O, 90 C.1515 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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explored,butrapiddecompositionofthestartingmaterialwas
observed. Hindered amines generally gave low yields as did
reactions with the 7-dimethylamino compound 19m.A l t e r -
natively, the alkylamines could be introduced prior to the
Michael-Dieckmann reaction using either palladium or cop-
per-mediatedaminations
22with16a,16d,and16e.Protection
ofthe resultingaminopyridinesupon treatmentwithLHMDS
followed by Boc2Oo rC b z C lg a v et h eD - r i n gp r e c u r s o r s22.
Michael-Dieckmann reaction then gave the protected inter-
mediates 23. Suzuki reactions with 19h or 19m and various
boronic acids were also carried out in moderate yields,
providing the 9-alkyl intermediates 25.D e p r o t e c t i o no ft h e
intermediates under standard conditions gave the ﬁnal 8-aza-
tetracyclines 24 and 26.
Biology. The in vitro antibacterial activities of all analogues
weredeterminedfor apanelof Gram-positive(e.g.,Staphylococcus
aureus and Streptococcus pneumoniae) and Gram-negative (e.g.,
Escherichia coli and Klebsiella pneumoniae) bacteria. The activities
of the 7-substituted-8-azatetracycline as well as several control
tetracyclines for a representative set of these organisms are found
in Table 1. The parent 8-azatetracycline 20a showed comparable
activity to tetracycline, with reasonable minimum inhibitory con-
centrations(MICs) of0.25-1μg/mLforthetetracycline-suscep-
tible strains. Lacking a substituent at either C-7 or C-9, 20a
demonstrated poor activity for the strains bearing tet(M), tet(K),
and tet(A). Overall, the 7-position appears to be very tolerant of
substitution, allowing for bulky (20e), electron withdrawing (20b
and 20i), and electron donating (20f and 20g)g r o u p sw h i l e
maintaining activity against the tetracycline-susceptible strains. As
with minocycline, introduction of the 7-dimethylamino group in
20fledtoimprovedactivitiesformoststrainstested.Modest(1-2
dilution) improvements in MICs were observed for the tet(M)
strains, while a more significant improvement was seen for the
strainbearingthetet(K)resistancemechanism.Withtheexception
ofthe7-chloroanalogue,allofthe7-substituted-8-azacompounds
exhibited improved MICs for the tet(K) strain, correlating well
with literature reports on 7-substituted tetracyclines. Unfortunately,
all of the 8-azatetracyclines appear to be substrates for the tet(A)
efflux pump, exhibiting no antibacterial activity at the highest
concentration tested (32 μg/mL). In general, substitution at the
7-position appears to be inefficient at overcoming the ribosomal
protection resistance mechanism of the tet(M) strains. The only
compound with two dilution improvements for both tet(M)
strains was compound 20i, the 7-fluoro analogue. This com-
pound was also one of the more potent antibacterial compounds
in this series.
To make a direct comparison to tigecycline, the 9-glycylami-
do-8-azatetracyclines were prepared (Table 2). Whereas tigecy-
clineisaverypotentantibacterialagentagainstalloftheorganisms
in our panel, including the four strains bearing tetracycline
resistance mechanisms, the corresponding 8-azatetracycline
analogues 21a-c were found to have poor overall activity.
T h ea n i l i n ep r e c u r s o r s20j and 20k, however, showed signiﬁ-
cant improvements in MICs for both tet(M) strains relative to
the corresponding 9-unsubstituted compounds 20b and 20i.
For the 7-Cl analogue 20j, antibacterial activity also improved
forthetet(K)andwildtypestrains.Thesecompoundswerealso
assessedfortheirabilitytoinhibitproteinsynthesisinacell-free
transcription/translation assay (Table 3). In this assay, com-
pounds 20j and 20k were about 2-fold more potent than
tetracycline, in agreement with their relative MICs for E. coli.
Compounds 21a-c, on the other hand, inhibited protein
synthesis with IC50s between 0.42 and 0.90 μg/mL, similar to
tigecycline, despite having only modest antibacterial activity in
the whole-cell assays. These data suggest that the compounds
are active at the target, but that compounds 21a-c are not
capable of getting to the target in the whole-cell assay, possibly
due to poor cell permeability.
On the basis of the results of compounds 20j and 20k, a series
of9-amino-8azatetracyclineswasprepared(Table4).Compounds
bearing a small, unbranched alkylamino group at the 9-position
(24a-c) proved to be very potent antibacterial agents against
Table 1. In Vitro Antibacterial Activity of 7-Substituted-8-azatetracyclines
MIC (μg/mL)
S. aureus S. pneumoniae E. coli K. pneumoniae
compd R1 wild type
a tet(M)
b tet(K)
c wild type
d tet(M)
c wild type
e tet(A)
c wild type
f
20a H 1 32 16 0.25 32 0.5 >32 1
20b Cl 1 32 32 1 32 2 >32 4
20d CH3 1 32 0.5 0.25 >32 1 >32 1
20e Ph 0.063 32 1 0.031 4 0.5 >32 2
20f (CH3)2N- 0.031 16 2 0.063 8 0.125 >32 0.25
20g CH3O- 0.125 8 4 0.063 16 0.25 >32 1
20i F 0.063 8 8 0.016 8 0.25 >32 0.5
tetracycline 1 >32 32 0.25 32 2 >32 4
minocycline 0.125 16 0.25 <0.016 8 0.5 8 1
aATCC 13709.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn Roberts’ lab at the University of Washington.
dATCC 49619.
eATCC 25922.
fATCC 13883.1516 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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the two tetracycline-susceptible Gram-positive strains, with MICs
between 0.016 and 0.25 μg/mL. A 4-fold improvement in activity
against the tet(M) S. aureus strain was observed for all of these
compounds relative to 20j, while MICs for the S. pneumoniae
tet(M) strain were largely unchanged. For the tet(K) S. aureus
strain, antibacterial activity improved with increasing size of the
alkyl group. Among the tetracycline-susceptible Gram-negative
strains, however, there was a clear loss in potency as the size of
the alkyl group increased, a trend that continued for the larger
branched alkyl compounds 24d-f. This is not surprising, as it is
known that Gram-negative antibacterial agents tend to be smaller
and more polar.
23 These larger side chains also adversely aﬀected
the antibacterial activity for S. pneumoniae while having less eﬀect
ontheMICsfortheS.aureusstrains.The7-ﬂuoro-9-n-propylamino
(24n) and 7-dimethylamino-9-n-propylamino (24o) analogues
were prepared as comparisons to 24c. While the 7-ﬂuoro
compoundhadMICsthattrackedfairlycloselytothe7-chloro
analogue, the 7-dimethylamino compound exhibited no anti-
bacterial activity for any of the strains at the highest concen-
tration tested (32 μg/mL) with the exception of the tetracycline-
susceptible S. pneumoniae strain. All three of the compounds had
similar, albeit weak, activity in the transcription/translation assay,
indicating the diﬀerences in MICs might be due to poor perme-
ability of the 7-dimethylamino analogue. Introduction of a more
polar heteroatom into the side chain (24g-i,k)r e s u l t e di n
improved antibacterial activity against the S. pneumoniae and
Gram-negative strains but had minimal eﬀect on activity
toward either resistant S. aureus organisms. Interestingly, the
oxygenbearingsidechains(24gand24h)yieldedsigniﬁcantly
improved antibacterial activity toward tetracycline-suscepti-
ble Gram-positive strains relative to the all carbon side chains
(24e and 24f), while the nitrogen analogues (24k and 24i)
were less potent against S. aureus a n ds h o w e dm o r em o d e s t
improvements against S. pneumoniae. The combination of a
branched side chain with a distal amino group gave the most
balancedantibacterialcompoundsinthisseries(24l,24m,and
24j). These compounds combine good antibacterial activity
toward both Gram-positive and Gram-negative organisms, with
modest activity against tet(A) E. coli.B o t hc o m p o u n d s24l and
24m are less potent than tigecycline but compare favorably to
amadacycline.
The antibacterial activity of the 9-alkyl and phenyl substituted
compounds were generally modest (Table 5). Here again, a
largersubstituentatC-9yieldedimprovedactivityfortet(M)and
tet(K) strains but resulted in loss of activity for wild type S.
pneumoniae and Gram-negative strains. Introduction of a 7-Cl or
7-dimethylamino group also gave improved activity for most of
Table 2. In Vitro Antibacterial Activity of 9-Glycylamido-8-azatetracyclines
aATCC 13709.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn Roberts’ lab at the University of Washington.
dATCC 49619.
eATCC 25922.
fATCC 13883.
Table 3. Transcription/Translation (TnT) Assay Data
compd E. coli
a MIC (μg/mL) TnT IC50 (μg/mL)
20f 0.125 0.76
20j 0.25 1.1
20k 0.25 0.93
21a 4 0.78
21b 8 0.36
21c 32 0.71
24i 8 0.58
24l 0.5 0.70
24c 4 5.3
24n 2 2.8
24o 32 3.4
tetracycline 2 2.0
tigecycline 0.125 0.47
aATCC 25922 is a tetracycline-susceptible strain.1517 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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the strains in the panel. When comparing the 7-Cl-9-alkyl
compounds (26b) to the 7-Cl-9-aminoalkyl compounds (24c),
itisclearthatthenitrogenconferssigniﬁcantimprovementsin
antibacterial activity. In the 7-dimethylamino case, however, the
7-dimethylamino-9-alkyl compound 26a is a balanced Gram-
positive antibacterial agent while the 9-aminoalkyl compound
24o has no signiﬁcant activity.
Compounds 20f and 24l were selected for further proﬁling.
Both compounds inhibited protein synthesis in the transcrip-
tion/translation assay with IC50s comparable to tigecycline.
Susceptibility testing was performed, and MIC50 and MIC90
values were calculated for recent clinical isolates of S. aureus, S.
pneumoniae, Haemophilus inﬂuenzae, and E. coli (Table 6). The
panels contained both tetracycline-susceptible and resistant
strains,including12methicillin-resistantS.aureus(MRSA)strains.
As expected from the initial MIC data, compound 20f had
very potent antibacterial activity for the tetracycline-suscep-
tible strains but performed poorly against the resistant
organisms. The compound did have MIC90st h a tw e r es i g -
niﬁcantly lower than tetracycline. Despite having higher
MICsintheprimaryscreenrelativetotigecycline,compound
24lperformedsimilarlyintheS.aureus, S.pneumoniae,andH.
inﬂuenzae panels, exhibiting clinically relevant MIC90s in each
case. These organisms are particularly relevant, as they are
responsible for infections in a large portion of community-
acquired bacterial pneumonia cases.
The pharmacokinetic proﬁles of the two 8-azatetracyclines
weredeterminedinSprague-Dawleyrats(Table7).Compound
20f had very similar AUC, clearance, and volume of distribution
proﬁlestobothtetracyclineandtigecycline,althoughthehalf-life
Table 4. In Vitro Antibacterial Activity of 9-Alkylamino-8-azatetracyclines
aATCC 13709.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn Roberts’ lab at the University of Washington.
dATCC 49619.
eATCC 25922.
fATCC 13883.1518 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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was somewhat shorter. Low oral bioavailability (%F) of 12.7%
was observed but was comparable to tetracycline (12.1%). In
humans, tetracycline is generally reported to have oral bioavail-
ability of 50-70%.
24 We and others have found the oral
bioavailability of several tetracycline derivatives to be signiﬁ-
cantly lower in rat than reported data in humans. Tigecycline,
administered only intravenously in humans, had very low oral
bioavailability. Compound 24l had a 4-fold higher AUC and
5-foldlower clearance thantheother threecompoundsas wellas
a signiﬁcantly lower volume of distribution. Unfortunately, oral
bioavailability was comparable to tigecycline.
The compounds were alsoinvestigated inmouse S. aureusand
E. coli septicemia models (Table 8). Both 8-azatetracyclines
performed well in the S. aureus model following IV administra-
tion, with PD50 values comparable to the two marketed control
tetracyclines. 20f, the most potent of the four compounds, also
provided the best protection, with 100% survival at the lowest
dose at which it was administered (0.30 mg/kg). Despite having
an 8-fold higher MIC, compound 24l provided equivalent
protection relative to tigecycline, likely due to its higher AUC
and lower clearance.
25 The E. coli model proved to be more
challenging, requiring higher doses for protection. Compound
20f had a PD50 of 4.3 mg/kg compared to 2.1 mg/kg for
tigecycline. Compound 24l was 4-fold less potent than 20f and
was comparable to tetracycline in this model.
Table 5. In Vitro Antibacterial Activity of 9-Alkyl-8-azatetracyclines
MIC (μg/mL)
S. aureus S. pneumoniae E. coli K. pneumoniae
compd R1 R2 wild type
a tet(M)
b tet(K)
c wild type
d tet(M)
c wild type
e tet(A)
c wild type
f
26a (CH3)2N n-Pr 1 2 1 1 2 16 >32 16
26b Cl n-Pr 1 4 4 1 4 >32 >32 32
26c Cl CH3 2 8 16 0.5 8 8 >32 8
26d HC H 3 4 32 32 1 16 8 >32 8
26e Cl Ph 1 2 1 8 8 >32 >32 >32
26f H Ph 4 8 16 2 8 16 >32 32
aATCC 13709.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn Roberts’ lab at the University of Washington.
dATCC 49619.
eATCC 25922.
fATCC 13883.
Table 6. MIC90 Analysis
species MIC (μg/mL) 20f 24l tigecycline tetracycline
S. aureus (n = 31) MIC50 e0.016 0.125 0.063 0.125
MIC90 16 2 1 >64
MIC range e0.016-32 0.063-4 e0.016-1 0.063f64
S. pneumoniae (n = 19) MIC50 2 e0.016 e0.016 32
MIC90 4 0.063 e0.016 >32
MIC range e0.016-8 e0.016-0.063 e0.016-e0.016 0.125f32
H. inﬂuenzae (n = 11) MIC50 0.5 1 0.5 4
MIC90 2 1 0.5 16
MIC range 0.063-4 0.25-2 0.25-1 0.25-16
E. coli (n = 20) MIC50 0.25 1 0.25 2
MIC90 >32 4 0.5 >64
MIC range e0.016-32 0.5-8 0.125-2 0.25f64
Table 7. Pharmacokinetic Properties of 20f and 24l in Spra-
gue-Dawley Rats
a
compd
AUC
(h3ng/mL)
Clobs
(mL/h/kg)
Vzobs
(mL/kg) t1/2 (hr) %F
20f 1087 919 4177 3.1 12.7
24l 4872 202 1256 4.3 0.8
tetracycline 802 1230 3676 4.5 12.1
tigecycline 1052 929 6119 4.6 1.1
aCompounds were dosed at 1 mg/kg IV and 10 mg/kg PO with sterile
water as vehicle.1519 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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’CONCLUSIONS
A novel, fully synthetic series of 8-azatetracycline analo-
gues was prepared and optimized. Through modiﬁcation of
the7-and9-positions,compoundswerefoundthatovercome
bothtet(K) eﬄuxandtet(M)-mediated ribosomal protection.
The 7-chloro-9-alkylamino-8-azatetracycline 24l exhibits
clinically relevant MIC90 proﬁles against both Gram-positive
and Gram-negative organisms that include these resistance
mechanisms. This compound also demonstrated in vivo eﬃcacy
in murine models of infection that is equivalent to currently
marketed tetracycline antibacterial agents. The 7-dimethylami-
no-8-azatetracycline 20f was eﬃcacious when administered
intravenously and had oral bioavailability in rat equivalent to
tetracycline.
The current work demonstrates the ability of this chem-
istry platform to generate antibacterial compounds that are
inaccessible through traditional semisynthesis, providing the
medicinal chemist a broader array of tools through which
essential antibacterial properties can be modulated. Impor-
tantly, this includes the ability to overcome ever evolving
resistance mechanisms and to identify structure-activity
relationships to deliver compounds with desired pharmaco-
kinetic properties.
’EXPERIMENTAL PROCEDURES
General. Air and moisture sensitive liquids and reagents were trans-
ferredviasyringeorcannulaandwereintroducedintoflame-driedglassware
underapositivepressureofdrynitrogenthroughrubbersepta.Allreactions
were stirred magnetically. Commercial reagents were used without further
purification. Analytical thin-layer chromatography was performed on EM
Science precoated glass-backed silica gel 60 Å F-254 250 μmp l a t e s .
Visualization of the plates was effected by ultraviolet illumination and/or
immersion of the plate in a basic solution of potassium permanganate in
water followed by heating. Column chromatography was performed
on a FlashMaster Personal system using ISOLUTE Flash Si II silica
gel prepacked cartridges (available from Biotage). Preparative reversed-
phaseHPLCchromatography(HPLC)wasaccomplishedusingaWaters
Autopurification system with mass-directed fraction collection. All inter-
mediate compounds were purified with a Waters Sunfire Prep C18 OBD
column(5μm,19mm 50mm;flowrate=20mL/min)usingamobile
phase mixture of H2O (A) and CH3CN (B) containing 0.1% HCO2H.
Thefinal8-azatetracyclinecompoundswerepurifiedusingaPhenomenex
Polymerx10μRP100Acolumn (10μm,30mm  21.2mm; flowrate=
20mL/min)usingamobilephasemixtureof0.05NHClinH2O(A)and
CH3CN (B). All final 8-azatetracycline compounds were isolated as
mono-, di-, or trihydrochloride salts following freeze-drying.
1H
NMR spectra were recorded on a JEOL ECX-400 (400 MHz) spectro-
meter and are reported in ppm using residual solvent as the internal
standard (CDCl3 at 7.24 ppm, DMSO-d6 at 2.50 ppm, or CD3OD at
3.31ppm).Highperformanceliquidchromatography-electrospraymass
spectra (LC-MS) were obtained using a Waters Alliance HPLC system
equippedwithabinarypump,adiodearraydetector,aWatersSunfireC18
(5 μm, 4.6 mm I.D.   50 mm) column, and a Waters 3100 series mass
spectrometerwithelectrosprayionization.Spectrawerescannedfrom100
to 1200 amu. The eluent was a mixture of H2O (A) and CH3CN (B)
containing 0.1% HCO2H at a flow rate of 1 mL/min. Purity of the final
compoundswasassessedbythefollowingmethod: (a) time=0,100%A;
(b)time=0.5min,100%A;(c)time=3.5min,100%B;(d)time=5min,
100% B (e) time = 6 min, 100% A; (f) time = 7 min, 100% A. All final
products were g95% purity as assessed by this method.
3-(Benzyloxy)-5-chloroisonicotinic Acid (12). Sodium hydride
(60% dispersion in mineral oil, 4.37 g, 109 mmol) was added portionwise
to a solution of 3,5-dichloroisonicotinic acid (10.2 g, 53.3 mmol) in NMP
(100mL).Aftergasevolutionceased,benzylalcohol(5.52mL,53.3mmol)
was added dropwise. After gas evolution ceased, the reaction mixture was
heated to 80 C. After 1 h, the reaction was complete and was allowed to
cool to room temperature and stand overnight. The reaction mixture was
d i l u t e dw i t hw a t e r( 3 0 0m L )a n dw a sw a s h e dw i t hE t 2O( 2  100 mL,
discarded).TheaqueouslayerwasbroughttopH∼2withconcHCl,causing
a precipitate to form. The mixture was diluted with brine (100 mL) and was
allowed to stand for 30 min. The solid was collected by filtration, was washed
withwater(3 ),andwasdriedina45Cvacuumovenovernight.Thisgave
9.36 g (67%) of the title compound as a white solid.
1HN M R( 4 0 0M H z ,
DMSO-d6)δ14.30-14.10 (bs, 1 H),8.52 (s, 1H),8.34 (s, 1H),7.50-7.30
(m, 5 H), 5.33 (s, 2 H). MS (ESI) m/z 264.20 (M þ H).
Phenyl 3-(Benzyloxy)-5-chloroisonicotinate (13). Oxalyl chlor-
ide(4.9mL,56mmol) wasaddedtoasuspensionof12(3.71g,14.1mmol)
in CH2Cl2 (50 mL) over ∼2 min. DMF was added dropwise in ∼20 μL
portions every 5 min until complete solution was achieved. After stirring for
an additional 30 min, the reaction mixture was concentrated under reduced
pressure. The resulting solid was dissolved in CH2Cl2(50 mL), and phenol
(2.65 g, 28.1 mmol), DMAP (0.172 g, 1.41 mmol), and Et3N( 9 . 7 6m L ,
70.4 mmol) were added. After 1 h, the reaction mixture was diluted with
CH2Cl2(50 mL) and was washed with water (2   100 mL) and NaHCO3
(saturated, aqueous, 100 mL). The organics were dried over Na2SO4,
filtered, and concentrated under reduced pressure. The material was
purified by column chromatography (Biotage 50 g column, 0-25%
EtOAcinhexanesgradient),yielding4.20g(88%)oftheproductasan
off-whitesolid.Rf =0.43in30%EtOAc/hexanes.
1HNMR(400MHz,
DMSO-d6) δ 8.70 (s, 1H), 8.48 (s, 1 H), 7.52-7.30 (m, 8 H), 7.15-
7.08 (m, 2 H), 5.44 (s, 2 H). MS (ESI) m/z 340.25 (M þ H).
Phenyl 3-(Benzyloxy)-5-methylisonicotinate (14). Compound
13 ( 2 . 0 1g ,5 . 9 2m m o l ) ,m e t h y lb o r o n i ca c i d( 1 . 0 6g ,1 7 . 7m m o l ) ,
dichlorobis(tricyclohexylphosphine)palladium(II) (102 mg, 0.296 mmol),
andK3PO4(3.76g,17.7mmol) wereheatedto100Cintoluene(20mL)
and water (2 mL). After 16 h, the reaction mixture was allowed to cool to
room temperature and was diluted with EtOAc (20 mL). This was washed
Table 8. IV Eﬃcacy in Mouse Septicemia Model
a
S. aureus E. coli
compd MIC (μg/mL) PD50 (mg/kg) 95% C.I. MIC (μg/mL) PD50 (mg/kg) 95% CI
20f 0.031 <0.30
b 0.13 4.3 4.1-4.6
24l 0.5 0.36 0.36-0.56 0.5 17 4.1-30
tetracycline 0.25 0.35 0.34-0.37 1 17 7.3-27
tigecycline 0.063 0.35 0.24-0.47 0.13 2.1 1.8-2.4
aS.aureusATCC13709(Smith)orE.coliATCC25922wasmixedwith5%mucinandinoculatedbyintraperitonealinjectionat2.1 10
6cfu/mouse(S.
aureus) or 2.0   10
7 cfu/mouse (E. coli). One hour postchallenge, mice received IV treatment (vehicle = sterile water) with the test article at
concentrations ranging from 0.05-10 mg/kg (S. aureus) or 0.30-30 mg/kg (E. coli). The PD50 in mg/kg was calculated as survival after 48 h.
bLowest
dose was 0.30 mg/kg with 100% survival at all doses.1520 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered, and
concentratedunder reducedpressure. The material was purified by column
chromatography (Biotage 50 g column, 0-40% EtOAc in hexanes
gradient), yielding 1.66 g (88%) of the product as a white solid. Rf =0 . 1 8i n
30% EtOAc/hexanes.
1H NMR (400 MHz, DMSO-d6) δ8.50 (s, 1H), 8.26
(s, 1 H), 7.52-7.30 (m, 8 H), 7.20-7.10 (m, 2 H), 5.37 (s, 2 H), 2.38 (s,
3 H). MS (ESI) m/z 320.27 (M þ H).
Phenyl 5-(Benzyloxy)-2-chloro-3-methylisonicotinate
(15a). Compound 14 (9.66 g, 30.3 mmol) was heated to 80 C in acetic
acid(50mL)andhydrogenperoxide(30%aqueoussolution,17mL).After
6 h, LC/MS indicated that the starting material was consumed and the
N-oxide present. Most of the acetic acid and water were removed under
reducedpressure.ThematerialwasthendilutedwithEtOAc(200mL),and
the mixture was washed with NaHCO3 (saturated aqueous solution, 3  
5 0m L ) .T h eo r g a n i c sw e r ed r i e do v e rN a 2SO4, filtered, and concentrated
under reduced pressure, yielding 9.37 g (92%) of the crude N-oxide. The
materialwasdissolvedintoluene(60mL),phosphorousoxychloride(7.69g,
50.1 mmol) was added, and the reaction mixture was heated to 100 C.
After2h,LC/MSindicatedthatthereactionwascomplete.Uponcoolingto
room temperature, the reaction mixture was poured into a solution of
K2CO3 (40 g) in water (200 mL). This mixture was extracted with EtOAc
(3 150mL),andthecombinedextractsweredriedoverNa2SO4,filtered,
and concentrated under reduced pressure.
1HN M Ri n d i c a t e dam i x t u r eo f
regioisomers (4.5:1). The material was redissolved in EtOAc (30 mL) with
heating and was then allowed to cool to room temperature and stand
overnight. A white crystalline solid was obtained (4.99 g, 51%). Another
1.92 g (19%) of the white crystalline solid was obtained from the mother
liquor after standing in a refrigerator overnight. Both were the desired pure
regioisomer15aby
1HNMR.
1HNMR(400MHz,CDCl3)δ8.05(s,1H),
7.43-7.30(m,7H),7.29-7.20(m,1H),7.07(d,J=8.2Hz,2H),5.21(s,
2 H), 2.46 (s, 3 H). MS (ESI) m/z 398.22, 400.22 (M þ H).
Phenyl 5-(Benzyloxy)-2-bromo-3-methylisonicotinate
(15b). Compound 14 (25.9 g, 81.1 mmol) was heated to 80 Ci n
acetic acid (160 mL) and hydrogen peroxide (30% aqueous solution,
40 mL). After stirring overnight, LC/MS indicated that the starting
material was consumed and the N-oxide present. The reaction mixture was
concentrated under reduced pressure, was diluted with EtOAc, and was
washed with NaHCO3 (saturated aqueous solution, 3 ). The organics
weredriedoverNa2SO4,filtered,andconcentratedunderreducedpressure,
yielding 25.4 g (93% crude) of the N-oxide as a tan solid. The material was
suspended in toluene (200 mL) and was heated to 80 C, at which point
most of the solid had dissolved. Phosphorousoxybromide (25 g, 87 mmol)
was added in one portion. After 30 min, LC/MS indicated the reaction was
complete. Upon cooling to room temperature, the reaction mixture was
pouredintoasolutionofK2CO3(83g)inwater(300mL).Thiswasstirred
for30minatroomtemperature.Thelayerswereseparated,andtheaqueous
layer was extracted with EtOAc. The combined extracts were dried over
MgSO4, filtered through Celite, and concentrated under reduced pressure.
The material was recrystallized from EtOAc/hexanes (1:1), yielding 20.6 g
(64%) of the product as an off-white solid. Single isomer by
1HN M R .
1H
NMR (400 MHz, CDCl3) δ8.05 (s, 1H),7.43-7.30 (m, 7 H),7.29-7.20
(m, 1 H), 7.07 (d, J = 8.2 Hz, 2 H), 5.21 (s, 2 H), 2.46 (s, 3 H). MS (ESI)
m/z 398.22, 400.22 (M þ H).
Phenyl 5-(Benzyloxy)-2-(dimethylamino)-3-methylisoni-
cotinate (15c). Compound 15b (1.06 g, 2.66 mmol), dimethylamine
(2.0 M solution in THF, 4.0 mL, 8.0 mmol), K3PO4 (1.7 g, 8.0 mmol),
tris(dibenzylideneacetone)dipalladium(120mg,0.13mmol),andXant-
phos (220 mg, 0.40 mmol) were heated to 100 C in 1,4-dioxane
(10mL)inasealedpressurevessel.Afterheatingovernight,thereaction
mixture was cooled to room temperature, was diluted with EtOAc
(100 mL), and was washed with water (3   50 mL) and brine (50 mL).
The organics were dried over Na2SO4, filtered, and concentrated under
reducedpressure. Thematerialwaspurifiedbycolumnchromatography
(Biotage 50 g column, 0-15% EtOAc in hexanes gradient), yielding
388 mg(40%) ofthetitlecompoundasawhitesolid.
1HNMR(400MHz,
CDCl3) δ 7.96 (s, 1H), 7.45-7.20 (m, 8 H), 7.08 (d, J =8 . 2H z ,
2 H), 5.16 (s, 2 H), 2.76 (s, 6 H), 2.37 (s, 3 H). MS (ESI) m/z 363.45
(M þ H).
Phenyl 5-(Benzyloxy)-2-methoxy-3-methylisonicotinate
(15d). Sodiummethoxide(38mg,0.70mmol)wasaddedtoasolution
ofcompound15b(118mg,0.351mmol)inNMP(2mL),andthereaction
mixture was heated to 100 C. After heating overnight, additional sodium
methoxide (57 mg, 1.1 mmol) was added and heating was continued at
100 C. After 1 h, the reaction mixture was heated to 120 C. After an
additional 1 h, the reaction mixture was cooled to room temperature, water
(20 mL) was added, and the pH was adjusted to 2 with 6 N aqueous HCl.
This was extracted with EtOAc (3   20 mL), and the combined extracts
weredriedoverNa2SO4,filtered,andconcentratedunderreducedpressure.
The crude acid intermediate was dissolved in CH2Cl2 (10 mL), and oxalyl
chloride (0.123 mL, 1.40 mmol) was added. After 1 h, the reaction mixture
was concentrated under reduced pressure. The material was dissolved
in CH2Cl2 (10 mL), and phenol (66 mg, 0.70 mmol), DMAP (4 mg,
0.04 mmol), and Et3N (0.245 mL, 1.76 mmol) were added. After 1 h,
the reaction mixturewas diluted with EtOAc (50 mL)and was washed
with water (2   30 mL) and brine (30 mL). The organics were dried
over Na2SO4, filtered, and concentrated under reduced pressure. The
material was purified by column chromatography (Biotage 10 g column,
0-12% EtOAc in hexanes gradient), yielding 20.3 mg (17%) of clean
product. An additional 29.1 mg of product contaminated with some
residual phenol was also isolated. Rf = 0.39 in 20% EtOAc/hexanes.
1H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 7.45-7.24 (m, 9 H),
7.10 (d, J= 7.3 Hz, 2 H), 5.13 (s, 2 H), 3.91 (s, 3 H), 2.67 (s, 3 H). MS
(ESI) m/z 336.1, 338.1 (M þ H).
Phenyl 3-(Benzyloxy)-2-bromo-6-chloro-5-methylisonicoti-
nate (16a). Compound 15a (4.99 g, 14.1 mmol) was dissolved in
CH2Cl2 (30 mL), and 3-chloroperbenzoic acid (77%, 6.33 g, 28.2 mmol)
was added in one portion. After 6 h, an additional portion of 3-chloroper-
benzoic acid (3.15 g, 14.1 mmol) was added, and the reactionwas stirred at
room temperature overnight. The reaction mixture was diluted with
CH2Cl2 ( 2 0 0m L )a n dw a sw a s h e dw i t hN a 2CO3 (saturated aqueous
solution,100mL)andbrine.TheorganicsweredriedoverNa2SO4,filtered,
a n dc o n c e n t r a t e du n d e rr e d u c e dp r e s s u r e .T h em a t e r i a lw a sp u r i f i e db y
column chromatography (Biotage 70 g column, 5-50% EtOAc in hexanes
gradient), yielding 3.90 g (75%) of the pure N-oxide as an off-white
solid(Rf=0.33in66%EtOAc/hexanes).TheN-oxidewasdissolvedin
toluene (30 mL), phosphorousoxybromide (6.36 g, 22.1 mmol) was
added, and the reaction mixture was heated to 80 C. After 1 h, the
reaction mixture was allowed to cool to room temperature and was
pouredintoasolutionofK2CO3(10g)inwater(50mL).Thismixture
was extracted with EtOAc (3   100 mL), and the combined extracts
weredriedoverNa2SO4,filtered,andconcentratedunderreducedpressure.
The material was purified by column chromatography (Biotage 50 g
column, 0-10% EtOAc in hexanes gradient), yielding 2.06 g (45%) of the
desired product 16a as an oil which slowly solidified on standing overnight.
In addition, 1.01 g (20%) of compound 15a was recovered.
1HN M R(4 0 0
MHz, CDCl3) δ 8.05 (s, 1H), 7.43-7.30 (m, 7 H), 7.29-7.20 (m, 1 H),
7.07(d,J=8.2Hz,2H),5.21(s,2H),2.46(s,3H).MS(ESI)m/z398.22,
400.22 (M þ H).
Phenyl3-(Benzyloxy)-2,6-dibromo-5-methylisonicotinate
(16b). Compound 15b (8.54 g, 21.4 mmol) was heated to 80 Ci n
acetic acid (120 mL) and hydrogen peroxide (30% aqueous solution,
30mL).Afterstirringovernight,LC/MSindicatedthatthestartingmaterial
was mostly consumed and the N-oxide present. The reaction mixture was
cooled to room temperature and was diluted with brine (150 mL). The
mixturewascooledina-20Cfreezerfor30min.Theresultingprecipitate
was collected byfiltrationand waswashedwithwater/brine(1:1, 2 ).The
solid was dissolved in CH2Cl2 a n dw a sd r i e do v e rN a 2SO4, filtered, and
concentrated under reduced pressure. This gave 7.83 g (88% crude) of the1521 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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N-oxideasatansolid.Thematerialwassuspendedintoluene(200mL)and
was heated to 100 C, at which point most of the solid had dissolved.
A solution of phosphorousoxybromide (10.8 g, 37.8 mmol) in toluene
(10 mL) was added rapidly. After 45 min, the reaction mixture was allowed
to cool to room temperature and was poured into a solution of K2CO3
(40g)inwater(150mL).Afterstirringfor30minatroomtemperature,the
layers were separated and the aqueous layer was extracted with EtOAc.
The combined extracts were dried over MgSO4, filtered, and concen-
trated under reduced pressure. The material was purified by column
chromatography (Biotage 50 g column, 0-8% EtOAc in hexanes gradient
toisolatetheproductthen15%EtOAcinhexanestorecover15b),yielding
5.02 g (49%) of the product as an off-white solid. Compound 15b was also
recovered.
1H NMR (400 MHz, DMSO-d6) δ 7.49-7.32 (m, 8 H), 7.10
(d, J = 7.3 Hz, 2 H), 5.15 (s, 2 H), 2.41 (s, 3 H). MS (ESI) m/z 476.18,
478.16, 480.16 (M þ H).
Phenyl 3-(Benzyloxy)-2-bromo-6-[(t-butoxycarbonyl)-
amino]-5-methylisonicotinate. Compound16b(2.15g,4.50mmol),
t-butylcarbamate (633 mg, 5.40 mmol), Cs2CO3 (2.93 g, 9.00 mmol), tris-
(dibenzylideneacetone)dipalladium (206 mg, 0.225 mmol), and Xantphos
(380 mg, 0.673 mmol) were weighed into a flask. This was evacuated and
backflushed with nitrogen (3 ), and 1,4-dioxane (15 mL) was added. The
reaction mixture was heated to 80 C. After 3 h, the reaction mixture was
cooled to room temperature, was diluted with EtOAc (100 mL), and was
washed with water (2   50 mL). The organics were dried over Na2SO4,
filtered,andconcentratedunderreducedpressure.Thematerialwaspurified
by column chromatography (Biotage 50 g column, 0-12% EtOAc in
hexanes gradient), yielding 1.43 g (62%) of a 4:1 mixture of the two
regioisomericcompounds.
1HNMR(400MHz,CDCl3)δ7.51-7.46(m,2
H), 7.42-7.32 (m, 7 H), 7.30-7.24 (m, 1 H), 7.12 (d, J = 8.2 Hz, 0.5 H),
7.03(d,J=8.2Hz,2H),6.88(s,0.25H),6.71(s,1H),5.12(s,2H),5.02(s,
0.5 H), 2.43 (s, 0.75 H), 2.34 (s, 3 H), 1.50 (s, 9 H), 1.47 (s, 2.25 H). MS
(ESI) m/z 535.10, 537.10 (M þ Na).
Phenyl 2-Amino-5-(benzyloxy)-6-bromo-3-methylisoni-
cotinate(16c). Theaboveregioisomericmixture(1.43g,2.78mmol)
was stirred in 4 M HCl in 1,4-dioxane (20 mL) and 1,4-dioxane (5 mL)
overnight. The reaction mixture was diluted with EtOAc (100 mL) and
was washed with NaHCO3 (saturated aqueous solution, 2   100 mL).
The organics were dried over Na2SO4, filtered, and concentrated under
reducedpressure. Thematerialwaspurifiedbycolumnchromatography
(Biotage 20 g column, 0-30% EtOAc in hexanes gradient), yielding
805 mg (70%) of the major regioisomer 16c and 270 mg (24%) of the
minor regioisomer. Data for 16c: Rf = 0.39 in 40% EtOAc/hexanes.
1H
NMR (400 MHz, CDCl3) δ 7.50-7.42 (m, 2 H), 7.40-7.30 (m, 5 H),
7.30-7.24(m,1H),7.04(d,J=8.2Hz,2H),5.06(s,2H),4.56(s,2H),
2.16 (s, 3 H). MS (ESI) m/z 413.11, 415.01 (M þ H). Data for phenyl
2-amino-3-(benzyloxy)-6-bromo-5-methylisonicotinate: Rf = 0.72 in
40% EtOAc/hexanes;
1H NMR (400 MHz, CDCl3) δ 7.42-7.34 (m,
8H),7.13-7.10(m,2H),5.01(s,2H),4.64(s,2H),2.35(s,3H);MS
(ESI) m/z 413.09, 415.09 (M þ H).
Phenyl3-(Benzyloxy)-2-bromo-6-fluoro-5-methylisonico-
tinate(16d). HF-Pyridinesolution(∼70%HF,2mL)wasaddedtoa
0 C solution of compound 16c (884 mg, 2.14 mmol) in pyridine (1 mL).
Sodium nitrite (177 mg, 2.57 mmol) was added (bubbling observed),
andthe reaction mixture wasallowedto slowlywarmto room temperature.
After 3 days, the reaction mixture was poured into Na2CO3 (saturated
aqueoussolution,30mL) andwasextractedwithEtOAc(3 30mL).The
combined extracts were washed with HCl (1 N aqueous solution, 2   50
mL)andweredriedoverNa2SO4,filtered,andconcentratedunderreduced
pressure.Thematerialwaspurifiedbycolumnchromatography(Biotage20
gcolumn,0-6%EtOAcinhexanesgradient),yielding687mg(77%)ofthe
productasa colorlessoil that slowly solidifiedonstanding. Rf=0.39i n1 0%
EtOAc/hexanes.
1H NMR (400 MHz, CDCl3) δ 7.50-7.42 (m, 2 H),
7.40-7.30 (m, 5 H), 7.30-7.24 (m, 1 H), 7.08-7.02 (m, 2 H), 5.14 (s, 2
H), 2.33 (s, 3 H). MS (ESI) m/z 416.17, 418.15 (M þ H).
Phenyl3-(Benzyloxy)-2-bromo-6-(dimethylamino)-5-methyli-
sonicotinate (16e) and Phenyl 3-(Benzyloxy)-6-bromo-
2-(dimethylamino)-5-methylisonicotinate (16f). Compound
16b (1.51 g, 3.16 mmol), Cs2CO3 (3.1 g, 9.5 mmol), tris(dibenzylide-
neacetone)dipalladium (145 mg, 0.158 mmol), and Xantphos (267 mg,
0.474 mmol)wereweighedintoavialequippedwithaseptum.Thiswas
evacuated and flushed with nitrogen (3 ), and 1,4-dioxane (7 mL) and
dimethylamine (2.0 M solution in THF, 4.75 mL, 9.50 mmol) were
added.Thereactionmixturewasheatedto60Candwasstirredfor4h.
The reaction mixture was allowed to cool to room temperature, was
filtered through Celite, and was concentrated under reduced pressure.
The material was purified by column chromatography (Biotage 50 g
column, 0-10% EtOAc in hexanes gradient), yielding 868 mg (58%) of
the major regioisomer 16e and 354 mg (24%) of the minor regioisomer
16f. Data for 16e:
1H NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2 H),
7.41-7.30 (m, 5 H), 7.30-7.24 (m, 1 H), 7.08-7.02 (m, 2 H), 5.08 (s,
2H),2.85(s,6H),2.32(s,3H);MS(ESI)m/z441.19,443.18(MþH);
Rf= 0.29 in 10% EtOAc/hexanes. The regiochemistry was confirmed by an
NOE between the methyl protons and the N,N-dimethylamino protons
(0.61%). Data for 16f:
1H NMR (400 MHz, CDCl3) δ 7.41-7.31 (m,
7H),7.30-7.20(m,1H),7.01(d,J=7.3Hz,2H),4.94(s,2H),3.04(s,
6H),2.33(s,3H);MS(ESI)m/z441.19,443.18(MþH);Rf=0.40in
10% EtOAc/hexanes.Theregiochemistry was confirmed by NOEbetween
the benzylic protons of the O-benzyl group and the N,N-dimethylamino
protons (0.44%).
Phenyl 5-Benzyloxy-6-[(t-butoxycarbonyl)amino]-2-fluoro-3-
methylisonicotinate(17a). Compound16d(538mg,1.29mmol),
t-butylcarbamate (302 mg, 2.58 mmol), Cs2CO3 (840 mg, 2.58 mmol),
tris(dibenzylideneacetone)dipalladium (59 mg, 0.065 mmol), and
Xantphos (109 mg, 0.190 mmol) were weighed into a flask. This was
evacuated and backflushed with nitrogen (3 ), and 1,4-dioxane (3 mL)
was added. The reaction mixture was heated to 80 C. After 4 h, the
reaction mixture was cooled to room temperature, was diluted with
EtOAc (50mL),andwaswashedwithwater(2 25mL).Theorganics
were dried over Na2SO4, filtered, and concentrated under reduced
pressure.Thematerialwaspurifiedbycolumnchromatography(Biotage
20 g column, 0-12% EtOAc in hexanes gradient), yielding 451 mg
(77%) of the product. Rf = 0.35 in 20% EtOAc/hexanes.
1H NMR (400
MHz,CDCl3)δ7.42-7.24(m,8H),7.04-6.99(m,2H),4.99(s,2H),
2.38 (s, 3 H), 1.40 (s, 18 H). MS (ESI) m/z 453.14 (M þ H).
Phenyl 3-Benzyloxy-2-[bis(t-butoxycarbonyl)amino]-
6-fluoro-5-methylisonicotinate (18a). Compound 17a (451 mg,
1.00 mmol) was treated with di-t-butyldicarbonate (1.09 g, 5.00 mmol)
and DMAP (24 mg, 0.20 mmol) in DMF (15 mL). After 30 min, the
reactionmixture was diluted with EtOAc (100 mL) and was washedwith
water (3   50 mL)and brine (50 mL). The organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure. The material
was purified by column chromatography (Biotage 10 g column, 0-8%
EtOAc in hexanes gradient), yielding 481 mg (87%) of the title
compound. Rf = 0.16 in 10% EtOAc/hexanes.
1H NMR (400 MHz,
CDCl3)δ7.42-7.24(m,8H),7.04-6.99(m,2H),4.99(s,2H),2.38(s,
3 H), 1.40 (s, 18 H). MS (ESI) m/z 575.25 (M þ Na).
Phenyl 5-Benzyloxy-6-[(t-butoxycarbonyl)amino]-2-(di-
methylamino)-3-methylisonicotinate(17b). Compound16e
(467 mg, 1.06 mmol), t-butylcarbamate (372 mg, 3.17 mmol), Cs2CO3
(1.04 g, 3.17 mmol), tris(dibenzylideneacetone)dipalladium (48 mg,
0.053 mmol), and Xantphos (89.3 mg, 0.159 mmol) were weighed
into a vial. This was evacuated and backflushed with nitrogen (3 ),
and 1,4-dioxane (3 mL) was added. The reaction mixture was heated
to 100 C. After 4 h, the reaction mixture was cooled to room
temperature and was filtered through Celite. The filtrate was con-
centrated under reduced pressure, and the material was purified by
column chromatography (Biotage 20 g column, 0-16% EtOAc in
hexanes gradient), yielding 493 mg (98%) of the product containing1522 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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∼20% of an unidentified impurity. Rf = 0.45 in 30% EtOAc/hexanes.
1H NMR (400 MHz, CDCl3) δ 7.43-7.32 (m, 8 H), 7.30-7.24 (m,
1 H), 7.15-7.10 (m, 2 H), 6.80 (s, 1 H), 4.94 (s, 2 H), 2.85 (s, 6 H),
2.31 (s, 3 H), 1.48 (s, 9 H). MS (ESI) m/z 478.27 (M þ H).
Phenyl 3-Benzyloxy-2-[bis(t-butoxycarbonyl)amino]-6-(di-
methylamino)-5-methylisonicotinate (18b). Compound 17b
(490 mg, 1.03 mmol) was treated with di-t-butyldicarbonate (672 mg,
3.08 mmol) and DMAP (12.5 mg, 0.103 mmol) in DMF (5 mL). After
stirringovernight,thereactionmixturewasdilutedwithEtOAc(25mL)
andwas washed with water(3   20mL) andbrine(20mL).Theorganics
weredriedoverNa2SO4,filtered,andconcentratedunderreducedpressure.
The material was purified by column chromatography (Biotage 10 g
column,0-10% EtOAcin hexanesgradient), yielding 424 mg(72%)
oftheproduct.Rf=0.22in15%EtOAc/hexanes.
1HNMR(400MHz,
CDCl3) δ 7.42-7.24 (m, 8 H), 7.06-7.00 (m, 2 H), 4.92 (s, 2 H), 2.79
(s, 6 H), 2.36 (s, 3 H), 1.39 (s, 18 H). MS (ESI) m/z 578.33 (M þ H).
(4aS,11aR,12aS,13S)-13-(Dimethylamino)-4a-[[(1,1-dimethyl-
ethyl)dimethylsilyl]oxy]-11a,12,12a,13-tetrahydro-5-hydro-
xy-3,7-bis(phenylmethoxy)-isoxazolo[50,40:6,7]naphth[2,3-g]-
isoquinoline-4,6(4aH,11H)-dione (19a). LDA was prepared
at-78Cfromn-butyllithium(1.6Msolutioninhexane,0.495mL,
0.792 mmol) and diisopropylamine (0.112 mL, 0.792 mmol) in THF
(5 mL). TMEDA (0.318 mL, 2.11 mmol) was added, followed by
dropwise addition of a solution of compound 14 (169 mg, 0.529
mmol)in THF (2 mL). This resulted inadeep-redcoloredsolution.
After 5 min, a solution of 8 (128 mg, 0.264 mmol) in THF (2 mL)
was added. After complete addition, the reaction mixture was
allowed to warm to -20 C over 1 h. The reaction was quenched
by the addition of ammonium chloride (saturated, aqueous solution,
20 mL) and was extracted with EtOAc (2   20 mL). The combined
extractsweredriedoverNa2SO4,filtered,andconcentratedunderreduced
pressure. The material was purified by preparative HPLC (Sunfire Prep
C18 column, 80-100% B gradient), yielding 65.5 mg (35%) of the title
compound as a yellow solid.
1H NMR (400 MHz, CDCl3) δ 15.77 (s,
1 H), 8.36 (s, 1 H), 8.16 (s, 1 H), 7.55-7.24 (m, 10 H), 5.40-5.25 (m,
4H),3.93(d,J=11.0Hz,1H),3.16-3.04(m,1H),2.98-2.90(m,1H),
2.76-2.64(m,1H),2.60-2.40(m,8H),2.12(d,J=14Hz,1H),0.82(s,
9 H), 0.26 (s, 3 H), 0.13 (s, 3 H). MS (ESI) m/z 708.72 (M þ H).
The following compounds were synthesized by methods similar to 19a.
(4aS,11aR,12aS,13S)-10-Chloro-13-(dimethylamino)-4a-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tet-
rahydro-5-hydroxy-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19b). Preparedfrom15ain38%yield,yellowsolid.
1HNMR(400MHz,
CDCl3)δ15.6(s,1H),8.12(s,1H),7.56-7.49(m,4H),7.42-7.32(m,
6H),5.37(s,2H),5.07(s,2H),3.91(d,J=11.0Hz,1H),3.13-3.02(m,
1 H), 2.97 (dd, J = 15.6 4.9 Hz, 1 H), 2.65-2.45 (m, 3 H), 2.50 (s, 6 H),
2.14 (d, J = 15.6 Hz, 1 H), 0.82 (s, 9 H), 0.27 (s, 3 H), 0.13 (s, 3 H). MS
(ESI) m/z 742.56 (M þ H).
(4aS,11aR,12aS,13S)-10-Bromo-13-(dimethylamino)-4a-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tet-
rahydro-5-hydroxy-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19c). Preparedfrom15bin71%yield,yellowsolid.
1HNMR(400MHz,
CDCl3) δ 15.55 (s, 1 H), 8.12 (s, 1 H), 7.55-7.24 (m, 10 H), 5.40-5.22
(m,4H),3.90(d,J=11.0Hz,1H),3.25(dd,J=16.5Hz,J=4.88Hz,1H),
3.12-3.02 (m, 1 H), 2.62-2.42 (m, 9 H), 2.14 (d, J= 14.0 Hz, 1 H), 0.82
(s,9H),0.26(s,3H),0.13(s,3H).MS(ESI)m/z786.63,788.63(MþH).
(4aS,11aR,12aS,13S)-10,13-Bis(dimethylamino)-4a-[[(1,
1-dimethylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tetra-
hydro-5-hydroxy-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19f). Preparedfrom 15cin50%yield,yellow solid.
1HNMR (400 MHz,
CDCl3)δ15.65(s,1H),8.01(s,1H),7.52-7.22(m,10H),5.36(s,2H),
5.17(q, J= 11.0 Hz, 2 H),4.02 (d, J=11.0Hz, 1 H), 3.05 (dd,J=17.2 Hz,
J= 11.6 Hz, 1 H), 2.98-2.86 (m, 1 H), 2.73 (s, 6 H), 2.62-2.38 (m, 9 H),
2.12 (d, J = 13.4 Hz, 1 H), 0.81 (s, 9 H), 0.26 (s, 3 H), 0.13 (s, 3 H). MS
(ESI) m/z 751.79 (M þ H).
(4aS,11aR,12aS,13S)-13-(Dimethylamino)-4a-[[(1,1-di-
methylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tetrahydro-
5-hydroxy-10-methoxy-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19g). Preparedfrom15din27%yield,yellowsolid.
1HNMR(400MHz,
CDCl3)δ15.70(s,1H),7.83(s,1H),7.55-7.24(m,10H),5.36(s,2H),
5.17(q, J=13.4Hz,2H),3.98(d,J=11.0Hz,1H),3.72(s,3H),3.18(d,
J = 16.5 Hz, 1 H), 3.04 -2.96 (m, 1 H), 2.60-2.30 (m, 9 H), 2.15 (d, J =
14 Hz, 1 H), 0.82 (s, 9 H), 0.26 (s, 3 H), 0.13 (s, 3 H). MS (ESI) m/z
738.66 (M þ H).
2-[(4aS,11aR,12aS,13S)-13-(Dimethylamino)-4a-[[(1,1-di-
methylethyl)dimethylsilyl]oxy]-10-fluoro-4,4a,6,11,11a,
12,12a,13-octahydro-5-hydroxy-4,6-dioxo-3,7-bis(phenyl-
methoxy)isoxazolo[50,40:6,7]naphth[2,3-g]isoquinolin-8-
yl]-imidodicarbonic Acid, 1,3-Bis(1,1-dimethylethyl) Ester
(19k). Preparedfrom18ain56%yield,yellowsolid.
1HNMR(400MHz,
CDCl3) δ 15.59 (s, 1 H), 7.56-7.24 (m, 10 H), 5.36 (s, 2 H), 4.92 (q, J=
67.8Hz, J=9.16Hz,2H),3.91(d,J=11.0Hz,1 H), 3.20-3.02(m, 2H),
2.62-2.45 (m, 9 H), 2.19-2.12 (m, 1 H), 1.37, (s, 18 H), 0.82 (s, 9 H),
0.26 (s, 3 H), 0.13 (s, 3 H). MS (ESI) m/z 941.59 (M þ H).
(4aS,11aR,12aS,13S)-8-Bromo-10,13-bis(dimethylamino)-
4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11a,12,12a,13-
tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19m). Preparedfrom16ein54%yield,yellowsolid.
1HNMR(400MHz,
CDCl3) δ 15.65 (s, 1 H), 7.52-7.22 (m, 10 H), 5.36 (s, 2 H), 5.17 (q, J =
11.0 Hz, 2 H), 4.01 (d, J= 11.0 Hz, 1 H), 3.05 (dd, J=1 7 . 2H z ,J= 11.6 Hz,
1 H), 2.98-2.86 (m, 1 H), 2.73 (s, 6 H), 2.62-2.38 (m, 9 H), 2.12 (d, J =
13.4 Hz, 1 H), 0.82 (s, 9 H), 0.26 (s, 3 H), 0.13 (s, 3 H). MS (ESI) m/z
829.49, 831.48 (M þ H).
(4aS,11aR,12aS,13S)-8-Bromo-10-chloro-13-(dimethyl-
amino)-4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11a,12,
12a,13-tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-is-
oxazolo[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-
dione (19h). Compound 16a (793mg, 1.84 mmol) andcompound 8
(885mg,1.84mmol)weredissolvedinTHF(16mL),andthesolutionwas
cooled to -78 C. LHMDS (1.0 M solution in THF, 5.5 mL, 5.5 mmol)
wasaddedslowlyviasyringe.After10min,thereactionmixturewasallowed
to slowly warm to 0 C over 1 h. A phosphate buffer solution (pH 7.0,
20 mL) was added, followed by the addition of ammonium chloride
(saturated, aqueous solution, 50 mL). The resulting mixture was
e x t r a c t e dw i t hC H 2Cl2 (3   50 mL), and the combined extracts were
driedoverNa2SO4,filtered,andconcentratedunderreducedpressure.
Theresulting brownsolid waswashed with cold methanol (3  5mL)
to afford 1.11 g (74%) of the title compound as a yellow-brown
powder. The organics were concentrated under reduced pressure and
purified by column chromatography (Biotage 20 g column, 5-20%
EtOAc in hexanes gradient), yielding an additional 150 mg (10%) of
the product.
1H NMR (400 MHz, CDCl3) δ 15.45 (br, 1 H), 7.54-
7.48 (m, 4 H), 7.40-7.30 (m, 6 H), 5.36 (s, 2 H), 5.03 (abq, J =1 0 . 4
Hz, 2 H), 3.87 (d, J = 11.0 Hz, 1 H), 3.27-3.23 (m, 1 H), 3.10-3.00
(m, 1 H), 2.65-2.57 (m, 1 H), 2.57-2.43 (m, 8 H), 2.16 (d, J =1 1 . 0
Hz, 1 H), 0.81 (s, 9 H), 0.26 (s, 3 H), 0.12 (s, 3 H). MS (ESI) m/z
820.37, 822.37 (M þ H).
The following compounds were prepared by methods similar to 19h.
(4aS,11aR,12aS,13S)-8-Bromo-13-(dimethylamino)-4a-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-10-fluoro-11a,12,
12a,13-tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-is-
oxazolo[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-
dione (19i). Prepared from 16d in 45% yield, yellow solid.
1H NMR1523 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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(400 MHz, CDCl3) δ 15.55 (s, 1 H), 7.56-7.26 (m, 10 H), 5.36 (s,
2 H), 5.02 (s, 2 H), 3.88 (d,J= 10.4 Hz, 1 H), 3.18-3.04 (m, 2 H), 2.62-
2.58(m,1H),2.58-2.40(m,8H),2.17(d,J=14.6Hz,1H),0.81(s,9H),
0.25 (s, 3 H), 0.12 (s, 3 H). MS (ESI) m/z 804.34, 806.34 (M þ H).
2-[(4aS,11aR,12aS,13S)-10,13-Bis(dimethylamino)-4a-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,4a,6,11,11a,12,
12a,13-octahydro-5-hydroxy-4,6-dioxo-3,7-bis(phenyl-
methoxy)isoxazolo[50,40:6,7]naphth[2,3-g]isoquinolin-8-
yl]-imidodicarbonicAcid,1,3-Bis(1,1-dimethylethyl)Ester
(19l). Preparedfrom18bin53%yield, yellow solid.
1HNMR(400MHz ,
CDCl3) δ 15.50 (s, 1 H), 7.52-7.24 (m, 10 H), 5.36 (s, 2 H), 4.85 (q, J=
86.1 Hz, J=9.76Hz,2H),4.02(d,J=10.4 Hz, 1H),3.08-3.00(m, 1H),
3.00-2.82 (m, 1 H), 2.77 (s, 6 H), 2.62-2.38 (m, 9 H), 2.20-2.12 (m,
1H),1.35,(brs,18H),0.79(s,9H),0.26(s,3H),0.12(s,3H).MS(ESI)
m/z 966.59 (M þ H).
(4aS,11aR,12aS,13S)-13-(Dimethylamino)-4a-[[(1,1-di-
methylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tetrahydro-
5-hydroxy-10-methyl-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19d). Asolutionofcompound19c(52mg,0.067mmol),methylboronic
acid(40mg,0.67mmol),dichloro[1,10-bis(diphenylphosphino)ferrocene]
palladium(II) dichloromethane adduct (3 mg, 0.003 mmol), and K3PO4
(142 mg, 0.667 mmol) in toluene (1 mL), 1,4-dioxane (1 mL), and water
(0.2mL) washeatedto70C.After2h,thereactionmixturewasheatedto
100C.Afteranadditional2h,thereactionmixturewasdilutedwithEtOAc
(20 mL) and was washed with water (15 mL) and brine (15 mL). The
organics were dried over Na2SO4, filtered, and concentrated under reduced
pressure. The material was purified by preparative HPLC (Sunfire Prep
C18 column, 80-100% B gradient), yielding 18.3 mg (38%) of the title
compoundasayellowsolid.
1HNMR(400MHz,CDCl3)δ15.71(s,1H),
8.24(s,1H),7.55-7.24(m,10H),5.36(s,2H),5.30-5.20(m,2H),3.95
(d, J = 10.4 Hz, 1 H), 3.10-2.92 (m, 2 H), 2.62-2.42 (m, 12 H), 2.12 (d,
J=14.0Hz,1 H),0.82(s,9 H), 0.26(s,3 H),0.14 (s,3H).MS(ESI) m/z
722.72 (M þ H).
(4aS,11aR,12aS,13S)-13-(Dimethylamino)-4a-[[(1,1-di-
methylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tetrahydro-
5-hydroxy-10-phenyl-3,7-bis(phenylmethoxy)-isoxazolo-
[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(19e). Asolutionofcompound19c(31mg,0.040mmol),phenylboronic
acid (24.5 mg, 0.201 mmol), dichloro[1,10-bis(diphenylphosphino)-
ferrocene]palladium(II) dichloromethane adduct (1.6 mg, 0.002 mmol),
and sodium carbonate (21.3 mg, 0.201 mmol)in toluene (1 mL), 1,
4-dioxane(1mL),andwater(0.2mL) washeatedto100Cviamicrowave
reactor for 10 min. The reaction mixture was diluted with EtOAc (10 mL)
and was washed with water (5 mL) and brine (5 mL). The organics were
dried over Na2SO4, filtered, and concentrated under reduced pressure. The
materialwaspurifiedbypreparativeHPLC(SunfirePrepC18column,80-
100%Bgradient),yielding16.9mg(54%)ofthetitlecompoundasayellow
solid.
1H NMR (400 MHz, CDCl3) δ 15.66 (s, 1 H), 8.48 (s, 1 H), 7.52-
7.24(m,15H),5.42-5.30(m,4H),3.97(d,J=10.4Hz,1H),3.00-2.86
(m, 2 H), 2.78-2.62 (m, 1 H), 2.58-2.30 (m, 8 H), 2.00 (d, J = 14.0 Hz,
1 H), 0.80 (s, 9 H), 0.25 (s, 3 H), 0.14 (s, 3 H). MS (ESI) m/z 784.75
(M þ H).
N-[(4aS,11aR,12aS,13S)-10-Chloro-13-(dimethylamino)-
4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,4a,6,11,11a,12,
12a,13-octahydro-5-hydroxy-4,6-dioxo-3,7-bis(phenyl-
methoxy)isoxazolo[50,40:6,7]naphth[2,3-g]isoquinolin-8-yl]-
carbamic Acid, 1,1-Dimethylethyl Ester (19j). Compound 19h
(100 mg, 0.122 mmol), t-butylcarbamate (42.9 mg, 0.366 mmol), K3PO4
(77.7 mg, 0.366 mmol), tris(dibenzylideneacetone)dipalladium (5.6 mg,
0.006 mmol), and Xantphos (10.3 mg, 0.018 mmol) were weighed into a
vial equipped with a septum. The vial was evacuated and flushed with
nitrogen (3 ), and 1,4-dioxane (0.5 mL) was added. The reaction mixture
was heated to 100 C and stirred for 2 h. The reaction mixture was allowed
to cool to room temperature, was filtered through Celite, and was
concentrated under reduced pressure. The material was purified by
preparative HPLC (Sunfire Prep C18 column, 80-100% B gradient),
yielding 41.7 mg (40%) of the title compound as a yellow solid.
1HN M R
(400MHz,CDCl3)δ15.65-15.45(brs,1H),7.56-7.50(m,2H),7.43-
7.34(m,7H),7.29-7.20(m,1H),5.38(s,2H),4.94(dd,J=29.3Hz,J=
11.0Hz,2H),3.90(d,J=11.0Hz,1H),3.27(dd,J=16.4Hz,J=11.6Hz,
1 H), 3.12-3.03 (m, 1 H), 2.68-2.60(m,1H),2.60-2.45 (m, 8 H), 2.18
(d,J=14.6Hz,1H),1.47(s,9H),0.85(s,9H),0.29(s,3H),0.15(s,3H).
MS (ESI) m/z 857.67 (M þ H).
6-Demethyl-6-deoxy-8-azatetracycline Dihydrochloride
(20a). Aqueous HF (48%, 0.4 mL) was added to a solution of 19a
(65.5 mg, 0.093 mmol) in CH3CN (0.6 mL) in a plastic vial. After 18 h,
thereactionmixturewaspouredintoasolutionofK2HPO4 (4.8 g)in
water (20 mL). The mixture was extracted with EtOAc (3   20 mL).
The combined extracts were dried over Na2SO4,f i l t e r e d ,a n dc o n -
centrated under reduced pressure. The material was dissolved in MeOH
(1mL)and1,4-dioxane(1mL),andpalladiumoncarbon(Degussa,10wt
%, ∼5 mg) was added. An atmosphere of hydrogen was introduced, and
the reaction mixture was stirred for 2 h.The reactionmixture was filtered
through Celite, and the filtrate was concentrated under reduced pressure.
The material was purified by preparative HPLC (Phenomenex Polymerx
column, 0-100% B gradient). Fractions with the desired MW were
collected and freeze-dried to yield 18.4 mg (41%, 2 steps) of the title
compound as a yellow solid.
1H NMR (400 MHz, CD3OD with 1 drop
DCl) δ 8.55 (s, 1 H), 8.36 (s, 1 H), 4.19 (s, 1 H), 3.26-2.98 (m, 9 H),
2.71(t,J=14.2Hz,1H),2.39-2.32(m,1H),1.75-1.63(m,1H).MS
(ESI) m/z 416.44 (M þ H).
The following compounds were synthesized by similar methods
to 20a.
7-Chloro-6-demethyl-6-deoxy-8-azatetracycline Hydro-
chloride(20b). Preparedfrom19bin24%yield,2steps,yellowsolid.
1HNMR(400MHz,CD3OD)δ8.08(d,J=6.0Hz,1H),4.09(s,1H),
3.08-2.92 (m, 9 H), 2.30-2.15 (m, 2 H), 1.70 -1.58 (m, 1 H). MS
(ESI) m/z 450.18 (M þ H).
6-Demethyl-6-deoxy-7-methyl-8-azatetracycline Dihy-
drochloride (20d). Prepared from 19d in 34% yield, 2 steps, yellow
solid.
1H NMR (400 MHz, CD3OD with 1 drop DCl) δ 8.35 (s, 1 H),
4.19 (s, 1 H), 3.25-2.95 (m, 9 H), 2.80-2.25 (m, 5 H), 1.80-1.63 (m,
1 H). MS (ESI) m/z 430.46 (M þ H).
6-Demethyl-6-deoxy-7-phenyl-8-azatetracycline Dihydro-
chloride (20e). Preparedfrom19ein24%yield,2steps,yellowsolid.
1HNMR(400MHz,CD3ODwith1dropDCl)δ8.53(s,1H),7.62 (s,
5H),4.18(s,1H),3.14-2.82(m,9H),2.81-2.66(m,1H),2.24-2.14
(m, 1 H), 1.66-1.52 (m, 1 H). MS (ESI) m/z 492.48 (M þ H).
6-Demethyl-6-deoxy-7-(dimethylamino)-8-azatetracy-
clineDihydrochloride(20f). Preparedfrom19fin96%yield,2steps,
yellowsolid.
1HNMR(400MHz,CD3ODwith1dropDCl)δ8.22(s,
1 H), 4.19 (s, 1 H), 3.38-3.30 (m, 2 H), 3.24 (s, 6 H), 3.12-2.95 (m,
7H),2.60(t,J=14.2Hz,1H),2.42-2.34(m,1H),1.75-1.63(m,1H).
MS (ESI) m/z 459.50 (M þ H).
6-Demethyl-6-deoxy-7-methoxy-8-azatetracycline Dihy-
drochloride (20g). Prepared from 19g in 51% yield, 2 steps, yellow
solid.
1H NMR (400 MHz, CD3OD with 1 drop DCl) δ 7.80 (s, 1 H),
4.15 (s, 1 H), 3.97 (s, 3 H), 3.40-2.98 (m, 9 H), 2.32-2.20 (m, 2 H),
1.72-1.56 (m, 1 H). MS (ESI) m/z 446.39 (M þ H).
6-Demethyl-6-deoxy-7-fluoro-8-azatetracycline Hydro-
chloride (20i). Prepared from 19i in 68% yield, 2 steps, yellow solid.
1HNMR(400MHz,CD3ODwith1dropDCl)δ7.81(s,1H),4.17 (s,
1 H), 3.26-2.96 (m, 9 H), 2.42-2.25 (m, 2 H), 1.70-1.58 (m, 1 H).
MS (ESI) m/z 434.27 (M þ H).
9-Amino-7-chloro-6-demethyl-6-deoxy-8-azatetracycline
(20j). Prepared from 19j in 68% yield, 2 steps, yellow solid.
1H NMR
(400 MHz, CD3OD with 1 drop DCl) δ 4.19 (s, 1 H), 3.20-2.98 (m,1524 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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8 H), 2.35-2.22 (m, 2 H), 1.68-1.56 (m, 1 H). MS (ESI) m/z 465.32
(M þ H).
9-Amino-6-demethyl-6-deoxy-7-fluoro-8-azatetracycline
Dihydrochloride (20k). Prepared from 19k in 49% yield, 2 steps,
yellow solid.
1H NMR (400 MHz, CD3OD with 1 drop DCl) δ 4.20 (s,
1 H), 3.40-2.90 (m, 9 H), 2.42-2.22 (m, 2 H), 1.70-1.54 (m, 1 H).
MS (ESI) m/z 449.27 (M þ H).
N-[(4aS,11aR,12aS,13S)-10-Chloro-13-(dimethylamino)-
4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,4a,6,11,11a,12,
12a,13-octahydro-5-hydroxy-4,6-dioxo-3,7-bis(phenyl-
methoxy)isoxazolo[50,40:6,7]naphth[2,3-g]isoquinolin-8-
yl]-2-[(1,1-dimethylethyl)amino]-acetamide. Compound 19j
(68.3 mg, 0.080 mmol) was stirred in 4 M HCl in 1,4-dioxane for 2 h.
The reaction mixture was concentrated under reduced pressure. The
material was dissolved in THF (2 mL), and bromoacetylchloride (12.5 mg,
0.080mmol)wasadded.Afterstirringovernight,anadditionalportion
of bromoacetylchloride (0.020 mL) was added. After 4 h, the reaction
mixture was concentrated under reduced pressure. MS (ESI) m/z
879.42(MþH).t-Butylamine(0.063mL,0.60mmol)wasaddedtoa
solution of the intermediate (35 mg, 0.040 mmol) in THF (1 mL),
andthereactionmixturewasheatedto50C.Afterstirringovernight,
the reaction mixture was concentrated under reduced pressure and
was purified by preparative HPLC (Sunfire Prep C18 column, 50-
100%Bgradient).Thisgave16.8mg(49%)ofthetitlecompoundasa
yellow solid.
1H NMR (400 MHz, CDCl3) δ 8.20 (br s, 1 H), 7.52-
7.46(m,2H),7.43-7.30(m,8H),5.36(s,2H),4.95(dd,J=40.6Hz,J=
11.0Hz,2H),3.88(d,J=11.0Hz,1H),3.32-3.24(m,1H),3.12-3.03
(m,1H),2.66-2.59(m,1H),2.58-2.42(m,8H),2.18(d,J=14 .6Hz ,
1H),1.30-1.10(brs,9H),0.82(s,9H),0.27(s,3H),0.12(s,3H).MS
(ESI) m/z 870.60 (M þ H).
9-[2-(tert-Butylamino)acetamido]-7-chloro-6-demethyl-
6-deoxy-8-azatetracyclineDihydrochloride(21a). Aqueous
HF (48%, 0.4 mL) was added to a solution of the preceding inter-
mediate (16.8 mg, 0.019 mmol) in CH3CN (0.6 mL) in a plastic vial.
After18h,thereactionmixturewaspouredintoasolutionofK2HPO4
(7.8 g) in water (15 mL). The mixture was extracted with EtOAc
(3 ).Sodiumchloride(10g)wasaddedtotheaqueouslayer,andthis
was extracted with EtOAc (2 ). The combined extracts were dried
over Na2SO4, filtered, and concentrated under reduced pressure.
ThematerialwasdissolvedinMeOH(1mL)and1,4-dioxane(1mL),
and palladium on carbon (Degussa, 10 wt %, ∼5 mg) was added. An
atmosphereofhydrogenwasintroduced,andthereactionmixturewas
stirred for 1 h. The reaction mixture was filtered through Celite, and
the filtrate was concentrated under reduced pressure. The material
was purified by preparative HPLC (Phenomenex Polymerx 10 μ RP
100A column, 0-100% B gradient). Fractions with the desired MW
were collected and freeze-dried to yield 1.2 mg (10%, 2 steps) of the
titlecompoundasayellowsolid.
1HNMR(400MHz,CD3ODwith1
drop DCl) δ 4.30-4.20 (s, 2 H), 4.19 (s, 1 H), 3.25-2.96 (m, 9 H),
2.48-2.28(m,2H),1.72-1.58(m,1H),1.43(s,9H).MS(ESI)m/z
578.48 (M þ H).
The following compounds were prepared according to methods
similar to 21a:
9-[2-(tert-Butylamino)acetamido]-6-demethyl-6-deoxy-
7-fluoro-8-azatetracycline Dihydrochloride (21b). Prepared
from 19k in 68% yield for the acylation/amine displacement and 58%
yield for the deprotections, yellow solid.
1H NMR (400 MHz, CD3OD
with 1 drop DCl) δ 4.24-4.65 (m, 3 H), 3.26-2.97 (m, 9 H), 2.38-
2.28(m,2H),1.69-1.56(m,1H),1.44(s,9H).MS(ESI)m/z562.37
(M þ H).
9-[2-(tert-Butylamino)acetamido]-6-demethyl-6-deoxy-
7-(dimethylamino)-8-azatetracycline Trihydrochloride
(21c). Prepared from 19l in 43% yield for the acylation/amine displace-
mentand55%yieldforthedeprotections,yellowsolid.
1HNMR(400MHz,
CD3OD with 1 drop DCl) δ 4.30-4.40 (m, 3 H), 3.40-3.25 (m, 8 H),
3.12-3 . 0 4( m ,4H ) ,2 . 9 9( s ,3H ) ,2 . 6 2 -2.52 (m, 1 H), 2.41-2.35
(m, 1 H), 1.73-1.60 (m, 1 H), 1.45 (s, 9 H). MS (ESI) m/z 587.43
(M þ H).
(4aS,11aR,12aS,13S)-10-Chloro-13-(dimethylamino)-4a-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-8-(ethylamino)-11a,
12,12a,13-tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-is-
oxazolo[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-
dione. Compound 19h(50mg,0.061mmol),K3PO4 (39mg,0.18
mmol), tris(dibenzylideneacetone)dipalladium (2.8 mg, 0.003 mmol),
andXantphos(5.1mg,0.009mmol)wereaddedtoasmallvialequipped
with a septum. After the flask was evacuated and flushed with nitrogen
(3 ), 1,4-dioxane (0.5 mL) and ethylamine (2.0 M solution in THF,
0.091 mL, 0.18 mmol) were added. The reaction mixture was heated to
100 C and stirred for 3 h. The reaction mixture was allowed to cool to
roomtemperatureandwasfilteredthroughCelite.Thematerialwaspurified
by preparative HPLC (Sunfire Prep C18 column, 90-100% B gradient).
FractionswiththedesiredMWwerecollectedandfreeze-driedtoyield
11mg(23%)ofthetitlecompoundasayellowsolid.
1HNMR(400MHz,
CDCl3) δ15.6(br, 1H),7.56-7.49 (m, 4H),7.42-7.30(m,6H),5.37
(s,2H),5.03(s,2H),3.89(d,J=11.0Hz,1H),3.24-3.04(m,3H),2.97
(dd,J=15.6,4.9Hz,1H),2.64-2.43(m,3H),2.49(s,6H),2.14(d,J=
15.6Hz,1H),1.25(t,J=6.8Hz,3H),0.81(s,9H),0.25(s,3H),0.11(s,
3 H). MS (ESI) m/z 785.57 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-(ethylamino)-8-azate-
tracycline Dihydrochloride (24a). Aqueous HF (48%, 0.3 mL)
was added to a solution of the preceding intermediate (11 mg, 0.014
mmol) in CH3CN (7 mL) in a plastic vial. After 18 h, the reaction
mixture was poured into a solution of K2HPO4 (2 g) in water (10 mL).
The mixture was extracted with EtOAc (3 ). The combined EtOAc
extracts were dried over Na2SO4 a n dc o n c e n t r a t e du n d e rr e d u c e d
pressure. The material was dissolved in MeOH (2 mL) and 1,4-dioxane
(2mL),andpalladiumoncarbon(Degussa,10wt%,5.6mg)wasadded.
An atmosphere of hydrogen was introduced, and the reaction mixture
wasstirredfor1h.ThereactionmixturewasfilteredthroughCelite,and
the filtrate was concentrated under reduced pressure. The material was
purified by preparative HPLC (Phenomenex Polymerx 10 μ RP 100A
column, 0-100% B gradient). Fractions with the desired MW were
collected and freeze-dried to yield 3.2 mg (46%, 2 steps) of the title
compound as a yellow solid.
1H NMR (400 MHz, CD3OD) δ 4.08 (s,
1H),3.43(q,J=7.4Hz,2H),3.08-2.92(m,9H),2.30-2.15(m,2H),
1.67-1.55 (m, 1 H), 1.22 (t, J = 7.4 Hz, 3H). MS (ESI) m/z 493.24
(M þ H).
The following compounds were prepared by similar methods to 24a:
7-Chloro-6-demethyl-6-deoxy-9-(methylamino)-8-azate-
tracyclineDihydrochloride(24b). Preparedfrom19handmethy-
lamine(1.0MsolutioninTHF)in21%yieldfortheaminationstep,19%
forthe2deprotectionsteps,yellowsolid.
1HNMR(400MHz,CD3OD)
δ 4.08 (s,1 H),3.41 (s,3 H),3.08-2.92 (m, 9H),2.30-2.15 (m, 2H),
1.67-1.55 (m, 1 H). MS (ESI) m/z 479.22 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-(propylamino)-8-azate-
tracyclineDihydrochloride(24c). Preparedfrom19handn-propyl-
amine in 24% yield for the amination step, 40% for the 2 deprotection steps,
yellow solid.
1H NMR (400 MHz, CD3OD with 1 drop DCl) δ 4.16
(s,1H),3.47(t,J= 7.3 Hz, 2 H), 3.15-2.96 (m, 9 H), 2.32-2.20(m,2H),
1.78-1.55 (m, 3 H), 1.01 (t, J = 7.4 Hz, 3 H). MS (ESI) m/z 507.29
(M þ H).
7-Chloro-6-demethyl-6-deoxy-9-(propan-2-ylamino)-8-
azatetracycline Dihydrochloride (24d). Prepared from 19h and
2-propylamine in 11% yield for the amination step, 16% for the 2
deprotectionsteps,yellowsolid.
1HNMR(400MHz,CD3OD)δ4.21-
4.13 (m, 1 H), 4.08 (s, 1 H), 3.14-2.92 (m, 9 H), 2.31-2.15 (m, 2 H),
1.67-1.56 (m, 1 H), 1.23 (dd, J = 6.4, 1.8 Hz, 6 H). MS (ESI) m/z
507.24 (M þ H).1525 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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7-Chloro-6-demethyl-6-deoxy-9-[(2-methylpropyl)amino]-
8-azatetracycline Dihydrochloride (24e). Prepared from 19h
and 2-methylpropan-1-amine in 15% yield for the amination step, 57%
for the 2 deprotection steps, yellow solid.
1H NMR (400MHz, CD3OD
with1dropDCl)δ4.18(s,1H),3.38(d,J=7.3Hz,2H),3.20-2.96(m,
9 H), 2.34-2.20 (m, 2 H), 2.10-1.98 (m, 1H), 1.68-1.54 (m, 1 H),
1.00 (d, J = 6.4 Hz, 6 H). MS (ESI) m/z 521.40 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-[(3-methylbutyl)amino]-
8-azatetracycline Dihydrochloride (24f). Prepared from 19h
and 3-methyl-butan-1-amine in 25% yield for the amination step, 66%
forthe2deprotectionsteps,yellowsolid.
1HNMR(400MHz,CD3OD)
δ 4.09 (s,1 H),3.45-3.40 (m,2 H),3.20 (s,1 H),3.08-2.93 (m, 9H),
2.30-2.16(m,2H),1.72-1.58(m,2H),1.55-1.48(m,2H),0.96(d,J=
6.4 Hz, 6 H). MS (ESI) m/z 535.30 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-[(2-methoxyethyl)amino]-
8-azatetracycline Dihydrochloride (24g). Prepared from 19h
and 2-methoxyethylamine in 19% yield for the amination step, 44% for
the2deprotectionsteps,yellowsolid.
1HNMR(400MHz,CD3ODwith1
drop DCl) δ 4.13 (s, 1H), 3.72-3.60 (m, 4H), 3.40 (s, 3 H), 3.12-2.95
(m,9H),2.32-2.21(m,2H),1.69-1.56(m,1H).MS(ESI) m/z523.32
(M þ H).
7-Chloro-6-demethyl-6-deoxy-9-[[2-(propan-2-yloxy)ethyl]-
amino]-8-azatetracycline Dihydrochloride (24h). Prepared
from 19h and 2-(propan-2-yloxy)ethan-1-amine in 9% yield for the
amination step, 30% for the 2 deprotection steps, yellow solid.
1H
NMR (400 MHz, CD3OD with 1 drop DCl) δ 4.19 (s, 1H), 3.82-
3.69 (m, 5H), 3.20-2.98 (m, 9 H), 2.35-2.22 (m, 2 H), 1.68-
1.56 (m, 1 H), 1.18 (d, J = 6.4 Hz, 6H). MS (ESI) m/z 551.41
(M þ H).
7-Chloro-6-demethyl-6-deoxy-9-[[3-(dimethylamino)propyl]-
amino]-8-azatetracycline Trihydrochloride (24i). Prepared
from 19h and (3-aminopropyl)dimethylamine in 9% yield for the
amination step, 21% for the 2 deprotection steps, yellow solid.
1H
NMR (400 MHz, CD3OD) δ 4.09 (s, 1 H), 3.70-3.46 (m, 4 H),
3.10-2.90 (m, 15 H), 2.31-2.17 (m, 2 H), 2.10-2.00 (m, 2 H),
1.68-1.56 (m, 1 H). MS (ESI) m/z 550.34 (M þ H).
Phenyl 3-(Benzyloxy)-2-[[(benzyloxy)carbonyl][3-(dimethyl-
amino)-2,2-dimethylpropyl]amino]-6-fluoro-5-methylpyr-
idine-4-carboxylate (22a). Compound 16d (100 mg, 0.24 mmol),
Cs2CO3(235mg,0.720mmol),tris(dibenzylideneacetone)dipalladium
(11 mg, 0.012 mmol), and Xantphos (20 mg, 0.036 mmol) were weighed
intoaflask.Thiswasevacuatedandbackflushedwithnitrogen(3 ),and
1,4-dioxane (0.5mL)andN,N-dimethylneopentanediamine(0.057mL,
0.36mmol)wereadded.Thereactionmixturewasheatedto70C.After
1.5 h, the reaction mixture was cooled to room temperature and was
filtered through Celite. The filtrate was concentrated under reduced
pressure and was purified by column chromatography (Biotage 10 g
column, 0-3% MeOH in CH2Cl2 gradient), yielding 76.9 mg (69%) of
theintermediate.Rf=0.25in5%MeOH/CH2Cl2.MS(ESI)m/z466.28
(M þ H). LHMDS (1.0 M in THF, 0.22 mL, 0.22 mmol) was added
dropwise to a -78 C solution of the above intermediate (93 mg, 0.20
mmol) in THF (5 mL). After 5 min, benzyl chloroformate (0.084 mL,
0.60mmol)wasadded.After15min,thereactionmixturewasquenched
by the addition of NH4Cl(saturated, aqueous solution, 15 mL) and was
extracted with EtOAc. The organics were dried over Na2SO4, filtered,
and concentrated under reduced pressure. The material was purified by
column chromatography (Biotage 10 g column, 0-7% MeOH in
CH2Cl2 gradient), yielding 111 mg (93%) of the product. Rf = 0.42 in
10% MeOH/CH2Cl2.
1H NMR (400 MHz, CDCl3) δ 7.45-7.20 (m,
13H),7.06-6.98(m,2H),5.16(s,2H),4.87(s,2H),3.78(brs,2H),
2.38(s,3H),2.18(brs,6H),1.62(brs,2H),0.90(brs,6H).MS(ESI)
m/z 600.28 (M þ H).
N-[(4aS,11aR,12aS,13S)-13-(Dimethylamino)-4a-[[(1,1-di-
methylethyl)dimethylsilyl]oxy]-10-fluoro-4,4a,6,11,11a,12,
12a,13-octahydro-5-hydroxy-4,6-dioxo-3,7-bis(phenyl-
methoxy)isoxazolo[50,40:6,7]naphth[2,3-g]isoquinolin-8-yl]-
N-[3-(dimethylamino)-2,2-dimethylpropyl]-carbamic Acid,
Phenylmethyl Ester (23a). A solution of compound 22a (54 mg,
0.090 mmol) in THF (0.5 mL) was added dropwise to a -78 C
solution of LDA (2.0 M solution in THF, 0.112 mL, 0.224 mmol) and
TMEDA(0.081mL,0.54mmol)inTHF(2mL),resultinginanorange-
colored solution. After 10 min, a solution of 8 (43 mg, 0.090 mmol) in
THF(0.5mL)wasaddeddropwiseover∼30s.Aftercompleteaddition,
the reaction mixture was allowed to warm to -10 C over 1 h. The
reaction was quenched by the addition of ammonium chloride (saturated,
aqueous solution), was diluted with water, and was extracted with EtOAc
(2 ). The combined extracts were dried over Na2SO4,f i l t e r e d ,a n d
concentrated under reduced pressure. The material was purified by
preparativeHPLC(SunfirePrepC18column,20-100%Bgradient),
yielding 22.9 mg (26%) of the desired product as a yellow solid.
1H
NMR (400 MHz, CDCl3) δ 15.55 (br s, 1 H), 7.52-7.20 (m, 15 H),
5.36(s,2H),5.20-5.00(m,2H),4.80(s,2H),3.90(d,J=11.0Hz,1
H), 3.19-3.05 (m, 2 H), 2.62-2.57 (m, 1 H), 2.56-2.12 (m, 19 H),
0.94-0.74 (m, 15 H), 0.26 (s, 3 H), 0.12 (s, 3 H). MS (ESI) m/z
988.59 (M þ H).
6-Demethyl-6-deoxy-9-[[3-(dimethylamino)-2,2-dimethyl-
propyl]amino]-7-fluoro-8-azatetracycline Trihydrochloride
(24j). A q u e o u sH F( 4 8 % ,0 . 4m L )w a sa d d e dt oas o l u t i o no f23a
(22.9 mg, 0.0232 mmol)in CH3CN (0.8 mL) in a plastic vial. After
18 h, the reaction mixture wasp o u r e di n t oas o l u t i o no fK 2HPO4
(4.8 g) in water. The mixture was extracted with EtOAc, and the
combined extracts were dried over Na2SO4, filtered, and concen-
trated under reduced pressure. The material was dissolved in MeOH
(1 mL), 0.5 M HCl in MeOH (0.2 mL), and 1,4-dioxane (1 mL), and
palladium on carbon (Degussa, 10 wt %, ∼2m g )w a sa d d e d .A n
atmosphere of hydrogen was introduced, and the reaction mixture
was stirred for 3 h. The reaction mixture was filtered through Celite,
and the filtrate was concentrated under reduced pressure. The
material was purified by preparative HPLC (Phenomenex Polymerx
column, 0-100% B gradient). Fractions with the desired MW were
collected and freeze-dried to yield 9.9 mg (67%, 2 steps) of the
desiredproductasayellowsolid.
1HNMR(400MHz,CD3ODwith1
dropDCl)δ 4.16( s,1H) ,3.43( s,2H) ,3.15-2.90(m,17H),2.30-
2.22 (m, 1 H), 2.22-2.12 (m, 1 H), 1.65-1.54 (m, 1 H), 1.17, (s, 6 H).
MS (ESI) m/z 562.43 (M þ H).
The following compounds were prepared according to methods
similar to 24j:
7-Chloro-6-demethyl-6-deoxy-9-[[2-(dimethylamino)ethyl]-
amino]-8-azatetracyclineTrihydrochloride(24k). Prepared
from 16a and N,N-dimethylethylenediamine. Yellow solid.
1HN M R
(400 MHz, CD3OD)δ 4.13 (s, 1 H), 3.84-3.77 (m, 2 H), 3.44-3.38
(m,2H),3.10-2.92(m,15H),2.32-2.20(m,2H),1.68-1.55(m,1H).
MS (ESI) m/z 536.25 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-[[3-(dimethylamino)-2,
2-dimethylpropyl]amino]-8-azatetracycline Trihydrochlor-
ide (24l). Prepared from 16a and N,N-dimethylneopentanediamine.
Yellow solid.
1H NMR (400 MHz, CD3OD) δ 4.10 (s, 1 H), 3.51-3.36
(m,4H),3.10-2.92(m,15H),2.33-2.18(m,2H),1.68-1.57(m,1H),
1.174 (s, 3 H), 1.169 (s, 3 H). MS (ESI) m/z 578.35 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-[[2-methyl-2-(pyrrolidin-
1-ylmethyl)propyl]amino]-8-azatetracycline Trihydrochlor-
ide (24m). Prepared from 16a and 2,2-dimethyl-3-(pyrrolidin-1-yl)-
propan-1-amine. Yellow solid.
1H NMR (400 MHz, CD3OD) δ 4.09
(s,1H),3.88-3.78(m,2H),3.50-3.39(m,2H),3.18-2.92(m,9H),
2.32-2.08 (m, 6 H), 1.67-1.56 (m, 1 H), 1.15 (s, 6 H). MS (ESI) m/z
604.29 (M þ H).
6-Demethyl-6-deoxy-7-fluoro-9-(propylamino)-8-azate-
tracycline Dihydrochloride (24n). Prepared from 16d and1526 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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n-propylamine. Yellow solid.
1H NMR (400 MHz, CD3OD) δ 4.09
(s, 1 H), 3.33 (t, J =6 . 9H z ,2H )3 . 4 2 -3.38 (m, 2 H), 3.20 (s, 1 H),
3.07-2.94(m,8H),2.91(dd,J =14.6,4.6Hz,1H),2.23-2.12(m,
2 H), 1.68-1.55 (m, 3 H), 0.96 (t, J =7 . 3H z ,3H ) .M S( E S I )m/z
491.23 (M þ H).
Phenyl5-Benzyloxy-2-(dimethylamino)-3-methyl-6-(propyl-
amino)isonicotinate. Copper(I) iodide (4.7 mg, 0.025 mmol) and
K3PO4 (209 mg, 0.984 mmol) were added to a vial equipped with a
septum. After the vial was evacuated and flushed with nitrogen (3 ), a
solution of compound 16e (217 mg, 0.492 mmol) in DMF (2 mL),
1-propylamine (0.162 mL, 1.97 mmol), and 2-acetylcyclohexanone
(0.013 mL, 0.098 mmol) were added. The reaction mixture was heated
to 100 C for 3 h. The reaction mixture was allowed to cool to room
temperature, was diluted with EtOAc (50 mL), and was washed with
water (3   40 mL). The organics were dried over Na2SO4, filtered, and
concentrated under reduced pressure. The material was purified by
column chromatography (Biotage 10 g column, 0-12% EtOAc in
hexanes gradient), yielding 74.6 mg (36%) of the title compound as a
thickoil.Rf=0.32in10%EtOAc/hexanes.
1HNMR(400MHz,CDCl3)
δ7.50-7.46(m,2H),7.41-7.30(m,5H),7.30-7.24(m,1H),7.08-
7.02 (m, 2 H), 5.08 (s, 2 H), 2.85 (s, 6 H), 2.32 (s, 3 H). MS (ESI) m/z
420.34 (M þ H).
Phenyl 5-Benzyloxy-6-[(t-butoxycarbonyl)(propyl)amino]-
2-(dimethylamino)-3-methylisonicotinate (22b). LHMDS
(1.0 M solution in THF, 0.167 mL, 0.167 mmol) was added to a
solution of phenyl 5-benzyloxy-2-(dimethylamino)-3-methyl-6-(propyl-
amino)isonicotinate (63.5 mg, 0.152 mmol) in THF (2 mL), resulting
in a bright-yellow solution. A solution of di-t-butyldicarbonate (99.5 mg,
0.456 mmol) in THF (1 mL) was added. After 10 min, the reaction was
quenchedbytheadditionofammoniumchloride(saturated,aqueous
solution) and was extracted with EtOAc (2 ). The organics were
dried over Na2SO4, filtered, and concentrated under reduced pres-
sure. The material was purified by column chromatography (Biotage
10 g column, 0-12% EtOAc in hexanes gradient), yielding 13.6 mg
(17%) of the product. Rf = 0.22 in 10% EtOAc/hexanes.
1HN M R
(400 MHz, CDCl3) δ 7.40-7.28 (m, 7 H), 7.28-7.22 (m, 1 H),
7.05-7.00 (m, 2 H), 4.90 (s, 2 H), 2.79 (s, 6 H), 2.34 (s, 3 H), 1.76-
1.66 (m, 2 H), 1.56-1.50 (m, 2 H), 0.91 (t, J = 7.56 Hz, 3 H). MS
(ESI) m/z 520.38 (M þ H).
N-[(4aS,11aR,12aS,13S)-10,13-Bis(dimethylamino)-4a-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,4a,6,11,11a,12,
12a,13-octahydro-5-hydroxy-4,6-dioxo-3,7-bis(phenyl-
methoxy)isoxazolo[50,40:6,7]naphth[2,3-g]isoquinolin-8-yl]-
N-propyl-carbamic Acid, 1,1-Dimethylethyl Ester (23b). A
solutionof22b(24mg,0.047mmol)inTHF(0.5mL)wasaddeddropwise
to a -78 C solution of LDA (0.5 M solution in THF, 0.102 mL, 0.051
mmol) and TMEDA (0.041 mL, 0.27 mmol) in THF (2 mL), resulting
in a yellowish-orange colored solution. After 10 min, a solution of 8
(16.4 mg, 0.034 mmol) in THF (0.5 mL) was added dropwise. After
completeaddition,thereactionmixturewasallowedtowarmto-20C
over ∼45 min. The reaction was quenched by the addition of ammo-
nium chloride (saturated, aqueous solution) and was extracted with
EtOAc (2 ). The combined extracts were dried over Na2SO4, filtered,
and concentrated under reduced pressure. The material was purified by
preparative HPLC (Sunfire Prep C18 column, 90-100% B gradient),
yielding6.1mg(20%) ofthedesired productasayellowsolid.
1HNMR
(400 MHz, CDCl3) δ 15.56 (s, 1 H), 7.52-7.24 (m, 10 H), 5.36 (s,
2H),4.99-4.64(m,2H),4.02(d,J=11.0Hz,1H),3.10-2.81(m,2H),
2.78 (s, 6 H), 2.62-2.40 (m, 10 H), 2.20-2.14 (m, 1 H), 1.80-1.45 (m,
2 H), 1.44-1.15 (m, 11 H), 1.00-0.70 (m, 12 H), 0.25 (s, 3 H), 0.12 (s,
3 H). MS (ESI) m/z 908.65 (M þ H).
6-Demethyl-6-deoxy-7-(dimethylamino)-9-(propylamino)-
8-azatetracycline Dihydrochloride (24o). Aqueous HF (48%,
0.4 mL) was added to a solution of 20o (6.1 mg, 0.007 mmol) in CH3CN
(0.6 mL) in a plastic vial. After 18 h, the reaction mixture was poured into a
solution of K2HPO4 (4.8 g) in water (15 mL). The mixture was extracted
withEtOAc(3 ).ThecombinedEtOAcextractsweredriedoverNa2SO4,
filtered, and concentrated under reduced pressure. The material was
dissolved in MeOH (1 mL) and 1,4-dioxane (1 mL), and palladium on
carbon(Degussa,10wt%,∼2mg) wasadded.Anatmosphereofhydrogen
was introduced, and the reaction mixture was stirred for 4 h. The reaction
mixture was filtered through Celite, and the filtrate was concentrated under
reduced pressure. The material was purified by preparative HPLC
(Phenomenex Polymerx, 0-100% B gradient). Fractions with the desired
MW were collected and freeze-dried to yield 2.8 mg (70%, 2 steps) of the
desiredproductasayellowsolid.
1HNMR(400MHz,CD3ODwith1drop
DCl) δ4.19 (s, 1H), 3.44 (t, J= 7.6 Hz, 2 H),3.24-3.12(m, 7 H), 3.12-
2.97(m,8H),2.39-2.26(m,2H),1.73-1.56(m,3H),0.98(t,J=8.4Hz,
3 H); MS (ESI) m/z 516.42 (M þ H).
(4aS,11aR,12aS,13S)-10,13-Bis(dimethylamino)-4a-[[(1,1-di-
methylethyl)dimethylsilyl]oxy]-11a,12,12a,13-tetrahydro-
5-hydroxy-3,7-bis(phenylmethoxy)-8-(2-propen-1-yl)-is-
oxazolo[50,40:6,7]naphth[2,3-g]isoquinoline-4,6(4aH,11H)-dione
(25a). Compound 19m (105 mg, 0.126 mmol), tetrakis(triphenyl-
phosphine)palladium(0) (15 mg, 0.013 mmol), and K3PO4 (80 mg,
0.38 mmol) were weighed into an 8 mL vial. This was sealed with a
septum and was evacuated and backflushed with nitrogen (3 ).
Toluene(1mL),1,4-dioxane(1mL),andwater(0.5mL)wereadded,
followed by allylboronic acid pinacol ester (63.7 mg, 0.379 mmol).
The reaction mixture was heated to 90 C. After 2.5 h, the reaction mixture
was cooled to room temperature and was concentrated under reduced
pressure.ThematerialwaspurifiedbypreparativeHPLC(SunfirePrepC18
column, 90-100% B gradient), yielding 28.6 mg (29%) of the title
compound as a yellow solid. MS (ESI) m/z 791.64 (M þ H).
6-Demethyl-6-deoxy-7-(dimethylamino)-9-propyl-8-aza-
tetracycline Dihydrochloride (26a). Aqueous HF (48%, 0.4 mL)
was added to a solution of 25a (28.6 mg, 0.036 mmol) in 1,4-dioxane
(1mL)inaplasticvial.After18h,thereactionmixturewaspouredintoa
solution of K2HPO4 (4.8 g) in water. The mixture was extracted with
EtOAc,andthecombinedextractsweredriedoverNa2SO4,filtered,and
concentrated under reduced pressure. The material was dissolved in
MeOH(1mL),0.5MHClinMeOH(0.5mL),and1,4-dioxane(1mL),
and palladium on carbon (Degussa, 10 wt %, ∼5 mg) was added. An
atmosphere of hydrogen was introduced, and the reaction mixture was
stirred for 1 h. The reaction mixture was filtered through Celite, and the
filtrate was concentrated under reduced pressure. The material was
purifiedbypreparative HPLC (PhenomenexPolymerxcolumn,0-70%
B gradient). Fractions with the desired MW were collected and freeze-
dried to yield 14.3 mg(69%) ofthe title compound as ayellow solid.
1H
NMR (400MHz, CD3ODwith1 dropDCl)δ 4.20 (s,1H),3.38-3.15
(m,7H),3.14-2.94(m,8H),2.91-2.82(m,2H),2.56(t,J=13.8Hz,
1 H), 2.40-2.32 (m, 1 H), 1.86-1.76 (m, 2 H), 1.74-1.62 (m, 1 H),
1.01 (t, J = 7.34 Hz, 3 H). MS (ESI) m/z 501.35 (M þ H).
The following compounds were prepared according to methods
similar to 26a:
7-Chloro-6-demethyl-6-deoxy-9-propyl-8-azatetracycline
Hydrochloride (26b). Prepared from 19h and allylboronic acid
pinacol ester, yellow solid.
1H NMR (400 MHz, CD3OD) δ 4.10 (s,
1 H), 3.22-2.92 (m, 9 H), 2.81-2.74 (m, 2 H), 2.49-2.38 (m, 1 H),
2.26-2.19 (m, 1 H), 1.77 -1.60 (m, 3 H), 0.97 (t, J = 7.3 Hz, 3 H). MS
(ESI) m/z 492.27 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-methyl-8-azatetracycline
Hydrochloride (26c). Prepared from 19h and methylboronic acid,
yellow solid.
1H NMR (400 MHz, CD3OD) δ 4.09 (s, 1 H), 3.22-
2.92 (m, 9 H), 2.85 (s, 3 H), 2.49-2.38 (m, 1 H), 2.26-2.19 (m, 1 H),
1.77 -1.60 (m, 1H). MS (ESI) m/z 464.30 (M þ H).
6-Demethyl-6-deoxy-9-methyl-8-azatetracyclineDihydro-
chloride (26d). Prepared from 19h as an over-reduced side product1527 dx.doi.org/10.1021/jm1015389 |J. Med. Chem. 2011, 54, 1511–1528
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in the synthesis of 26c.
1H NMR (400 MHz, CD3OD) δ 7.78 (s, 1 H),
4.12 (s, 1 H), 3.22-2.91 (m, 9 H), 2.78 (s, 3 H), 2.49-2.21 (m, 1 H),
1.77-1.62 (m, 1H). MS (ESI) m/z 430.46 (M þ H).
7-Chloro-6-demethyl-6-deoxy-9-phenyl-8-azatetracycline
Hydrochloride (26e). Prepared from 19h and phenylboronic
acid.
1H NMR (400 MHz, CD3OD) δ 8.04-7.98 (m, 2 H),
7.47-7.39 (m, 3 H), 4.08 (s, 1 H), 3.14-2.92 (m, 9 H), 2.57-
2.47 (m, 1 H), 2.28-2.07 (m, 1 H), 1.73-1.65 (m, 1H). MS (ESI)
m/z 526.26 (M þ H).
6-Demethyl-6-deoxy-9-phenyl-8-azatetracycline Dihydro-
chloride(26f). Preparedfrom19hasanover-reducedsideproductin
the synthesis of 26e.
1H NMR (400 MHz, CD3OD) δ 8.04-7.98 (m,
2H),7.47-7.39(m,3H),4.08(s,1H),3.14-2.92(m,9H),2.57-2.47
(m, 1 H), 2.28-2.07 (m, 1 H), 1.73-1.65 (m, 1H). MS (ESI) m/z
526.26 (M þ H).
Susceptibility Testing. Compound stocks were prepared in
sterile deionized water. Tetracycline-susceptible isolates SA100
(S. aureus ATCC 13709, Smith), SA101 (S. aureus ATCC 29213),
SP106 (S. pneumoniae ATCC 49619), EF103 (E. faecalis ATCC
29212), EC107 (E. coli ATCC 25922), KP109 (K. pneumoniae
ATCC 13883), AB110 (Acinetobacter baumannii ATCC 19606),
EC108 (Enterobacter cloacae ATCC 13047), and PA111 (Pseudomonas
aeruginosa ATCC 27853) were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Tetracycline-resistant
isolates S. aureus SA158 (tet(K)), S. pneumoniae SP160 (tet(M)),
E. faecalis EF159 (tet(M)), E. coli EC155 (tet(A)), K. pneumoniae
KP153 (tet(A)) were obtained from Marilyn Roberts’ lab at the
University of Washington. S. aureus SA161 (tet(M)) was obtained from
Micromyx (Kalamazoo, MI). Minimal inhibitory concentration
(MIC)determinations wereperformed in liquid medium in 96-well
microtiterplatesaccordingtothemethodsdescribedbytheClinical
and Laboratory Standards Institute (CLSI).
26 Cation-adjusted
Mueller Hinton broth was obtained from BBL (cat. no. 212322,
Becton Dickinson, Sparks, MD), prepared fresh and kept at 4 C
prior to testing. Defibrinated horse blood (cat. no. A0432, PML
Microbiologicals, Wilsonville, OR) was used to supplement med-
ium, as appropriate. All test methods met acceptable standards
based on recommended quality control ranges for all comparator
antibiotics and the appropriate ATCC quality control strains.
In vitro Transcription/Translation Assay. Compound stocks
prepared and diluted in sterile deionized water were assayed for
inhibition of coupled in vitro transcription/translation using an E. coli
S30 extract system with a firefly luciferase readout from Promega (cat.
no. L1020, Madison, WI). Briefly, compounds were diluted into water
and added to reaction mix aliquoted to black-walled 96-well microtiter
plates (cat. no. 3650, Costar, Corning, NY). An appropriate three-point
titration was used for each compound, and reactions were run in
duplicate. The final total reaction volume was 20 μL. Plates were
incubated at 37 C for one hour and then placed on ice for 5 min to
arrest transcription/translation. Luciferase substrate (25 μL, Promega
cat. no. E1500) was added to each well and luminescence was detected
on a BMG LabTech LUMIstar-OPTIMA instrument. Positive assay
controlvalues,fromreactions withoutinhibitor, were averagedper plate
to determine percent inhibition of luciferase production. Results were
plotted using Microsoft Excel and 50% inhibition values (IC50) were
determined.
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